Document:

exv10w31

Exhibit 10.31

EXCLUSIVE LICENSE AND SPONSORED RESEARCH AGREEMENT

between

OMEROS CORPORATION and MEDICAL RESEARCH COUNCIL

     This license agreement (the “Agreement”) is made effective the 31st day of October 2005 (the
“Effective Date”) between Omeros Corporation, a Washington corporation having a principal place of
business at 1420 Fifth Avenue, Suite 2600, Seattle WA 98101 USA (“Omeros”) and Medical Research
Council, a United Kingdom governmental institution having a place of business at 20 Park Crescent,
London, United Kingdom, W1B 1AL (“MRC”).

     WHEREAS MRC owns rights to certain technology related to mannan-binding lectin associated
serine protease-2 (“MASP-2”), which technology was developed in part by Anthony C. Willis (“Mr.
Willis”) working in an MRC laboratory under the direction of Professor Kenneth B. M. Reid (“Dr.
Reid”), both employees of MRC;

     WHEREAS Omeros holds an exclusive, worldwide license to rights owned by the University of
Leicester (“Leicester”) related to the MASP-2 technology due to the development in part of the
MASP-2 technology by Leicester’s employees;

     WHEREAS Omeros wishes to undertake an exclusive license to MRC’s rights in the MASP-2
technology, and to sponsor further research by MRC to develop the MASP-2 technology at MRC, under
the direction of Dr. Reid, working in collaboration with Omeros and Leicester; and

     WHEREAS MRC wishes to grant Omeros an exclusive license in MRC’s rights to the MASP-2
technology in return for potential royalty payments and sublicense revenue sharing, and to accept
payment for such sponsored research;

     NOW THEREFORE, in consideration for the mutual covenants and obligations set forth herein as
well as other good and valuable consideration, the parties hereby agree as follows:

	1	 	Definitions
	 
	1.1	 	Reference to “MRC” and “Omeros” in regards to any intellectual property right developed by
the respective party shall be construed to refer to the respective party as well as the
respective party’s employees, officers, directors, consultants and agents.
	 
	1.2	 	“Intellectual Property Rights” shall mean all inventions, ideas, discoveries, issued,
reissued or reexamined patents, pending and future patent applications, continuation,
continuation-in-part and divisional patent applications, utility models, inventor’s
certificates, trade secrets, know-how, copyrights and trademarks.
	 
	1.3	 	“Sponsored Research” shall mean all research activities carried out by MRC and/or its
employees (as may be agreed by MRC and Omeros) with the financial sponsorship, in whole or in
part, by Omeros in accordance with Section 2 herein below or as otherwise agreed.

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-1-

 

	1.4	 	“MRC IP” shall mean all Intellectual Property Rights owned or held by MRC, including without
limitation all such Intellectual Property Rights arising from the work of Mr. Willis, Dr. Reid
and/or other MRC employees, prior to the Effective Date of this Agreement, or developed or
obtained by MRC after the Effective Date of this Agreement both (a) independently of Omeros
(as determined by inventorship under US law with respect to any patents and patent
applications) and (b) independently of the Sponsored Research, provided always that any of the
Intellectual Property Rights described above in this section 1.4 are directly related to
compositions, antibodies and/or methods for the inhibition of MASP-2 and/or the diagnosis
and/or treatment of MASP-2 mediated disorders and/or deficiency syndromes, as well as methods,
polynucleotides, polypeptides, sequences and tools related to the development and production
of MASP-2 antibodies, including without limitation murine, human, humanized and recombinant
antibodies, MASP-2 inhibitors, [†].
	 
	1.5	 	“Omeros IP” shall mean all Intellectual Property Rights owned or held by Omeros prior to the
Effective Date of this Agreement, or developed or obtained by Omeros after the Effective Date
of this Agreement independently of MRC (as determined by inventorship under US law with
respect to any patents and patent applications), including without limitation all such
Intellectual Property Rights (a) related to MASP-2 obtained by Omeros under license from
Leicester (including without limitation all MASP-2 and MAp19 rights conveyed under the
Omeros-Leicester Agreement of 10 June 2004) or developed by Omeros independently of MRC by
Omeros and (b) related to methods and pharmaceuticals or other agents to inhibit pain,
inflammation, cartilage loss, vasospasm, smooth muscle spasm, restenosis, or tumor cell
adhesion, and/or to accelerate recovery of joint motion and function, for use in surgical
procedures (including without limitation arthroscopic, cardiovascular, urologic and general
surgical procedures), other medical procedures, and/or for treatment of cartilaginous
disorders, and drug delivery methods and systems.
	 
	1.6	 	“Joint IP” shall mean (a) all Intellectual Property Rights in technology that is developed
jointly (as determined by inventorship with respect to any patents and patent applications) by
Omeros and MRC (as may be agreed by MRC and Omeros) during the Sponsored Research Term (as
that term is defined in Section 2.2 herein), and (b) all Intellectual Property Rights arising
from and as the direct result of the Sponsored Research. Joint IP may or may not also be
jointly developed with Leicester or other third party, which will not change the nature of the
Intellectual Property Rights as Joint IP so long as the first sentence of this Section
applies. Should any MRC employee enter into a consulting agreement with Omeros for general
scientific consulting such as in the field of inflammation, then to the extent that such
scientific consulting services may pertain to MASP-2, the results of such scientific
consulting services will be treated as part of the Joint IP. However, the parties acknowledge
herein that research by MRC employees on behalf of Omeros related to MASP-2 will be carried
out in major part through the Sponsored Research.

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-2-

 

	1.7	 	[†]
	 
	1.8	 	“Licensed Products” shall mean all antibodies, inhibitors and all other products that, were
it not for the license granted to Omeros under this Agreement, infringe, or the use,
manufacture, offer for sale or sale of which infringe any valid and subsisting claim(s) of any
issued patent or any patentable claim(s) of any pending patent application included within the
MRC IP in the country or countries in which such products are offered for sale, sold,
manufactured or used, excluding all products that would be included within the Licensed
Products in accordance with the above definition only because they are products that [†].
	 
	1.9	 	“Net License Proceeds” shall mean the total of the gross monetary amounts invoiced and
collected by Omeros for Licensed Products (or that portion of the value of any combination
product attributed to a Licensed Product included therein) used, manufactured, directly sold
or directly distributed by Omeros, less (a) the sum of the following actual and customary
deductions where applicable: cash, trade, or quantity discounts; sales, use, tariff,
import/export duties or other excise taxes, and any other governmental taxes imposed on
particular sales; transportation charges and allowances; commissions to third party sales
agents; and credits to customers because of rejections or returns and (b) any accrued Omeros
IP Legal Fees (as defined below) not previously deducted. For purposes of this paragraph, the
acquisition of Licensed Products from Omeros as part of an acquisition of all or a substantial
part of the assets of Omeros’ business to which this Agreement pertains shall not be
considered a manufacture, sale or distribution.
	 
	1.10	 	“Net Sublicense Proceeds” shall mean the total of all sublicense royalties or sublicense fees
received by Omeros from third parties to which Omeros grants a sublicense under the MRC IP for
the manufacture, sale or distribution of Licensed Products, and which were not included in the
Net License Proceeds, less any accrued Omeros IP Legal Fees not previously deducted, provided
however that the Net Sublicense Proceeds shall not include any fees or payments from such
third parties to Omeros to support research and development efforts, to purchase equity in
Omeros, or for any other purpose other than as compensation for sublicense rights.
	 
	1.11	 	“Omeros IP Legal Fees” shall mean the sum of all legal fees and costs incurred by Omeros to
(a) evaluate, apply for, prosecute and maintain any Intellectual Property Rights included
within the MRC IP, including without limitation any such fees and costs paid by Omeros as
reimbursement to MRC for such fees and costs incurred by MRC, and (b) obtain or assist MRC in
obtaining or attempting to obtain clear, defensible, lawful and uncontested title to the MRC
IP, including without limitation all such fees and costs incurred in [†].
	 
	1.12	 	“Third Party License Fees” shall mean all royalties or other fees paid by Omeros to third
parties for a license from such third parties under Intellectual Property Rights owned or held
by such third parties for the manufacture, use, offer for sale, sale or distribution of
Licensed Products, but shall exclude that portion of any such third party royalties

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-3-

 

(including without limitation royalties payable to Leicester) or other fees paid by Omeros
attributed to items sold in combination with the Licensed Products, which items are not
Licensed Products.

	2	 	Sponsored Research
	 
	2.1	 	MRC shall perform research to be conducted by or under the direction of Dr. Reid and another
MRC senior research investigator (the “MRC Co-investigator”) working under the direction of
Dr. Reid as may be agreed between MRC and Omeros (Dr. Reid and the MRC Co-investigator
collectively “MRC Investigators”), directed to advancing the technology included in the MRC IP
or related technology concerning the characterization and inhibition of MASP-2, supported by
the financial sponsorship of Omeros, and without the use of third party sponsorship that would
provide any intellectual property rights in the results of the Sponsored Research to such
third party, in accordance with one or more research plans (“Research Plans”) agreed to in
advance in writing between MRC and Omeros. An initial Research Plan is attached hereto as
Exhibit A. The Research Plans may involve collaborative research efforts by Omeros, MRC
and/or Leicester as may be agreed between MRC and Omeros. No Research Plan or any amendment
thereto shall be effective until executed by MRC and Omeros, and upon mutual execution shall
be automatically incorporated into this Agreement. Each Research Plan shall define scientific
aims, objectives and activities, a budget and a timeline for performance of Sponsored Research
during the corresponding time period.
	 
	2.2	 	The Sponsored Research shall be completed over a term (the “Sponsored Research Term”) of
thirty four months (34 months) commencing 1 November 2005 or as may otherwise be mutually
agreed in writing. If Omeros or MRC wishes to terminate the Sponsored Research Term early,
such party shall provide the other party notice of non-extension at least ninety (90) days
prior to the end of any given year of the Sponsored Research term, i.e., by 3 August of such
year. In the event of a breach of this Agreement by MRC during the Sponsored Research Term,
Omeros may terminate the Sponsored Research Term as provided in accordance with Section 14.4
below at its sole discretion, without penalty. If Omeros should terminate the Sponsored
Research Term as provided in accordance with Section 14.4 below for any other reason before
completion of the full Sponsored Research Term, or upon completion of the full Sponsored
Research Term, Omeros will reimburse MRC for any legally required severance payable to the MRC
Co-investigator due solely to the termination or conclusion of the Sponsored Research, not to
exceed [†], provided, however that MRC will utilize its best efforts to minimize or avoid the
need for any such payment, including without limitation efforts to find other support for the
MRC Co-investigator, and provided further that MRC shall provide Omeros with documentation of
the legal requirement for and amount of any such severance. The Sponsored Research Term shall
run independently of the License Term (as defined herein below) of this Agreement.
Termination of this Agreement shall result in termination of the Sponsored Research Term, but
termination of the Sponsored Research Term, such as in accordance with this Section 2.2 or
Section 14.4 herein, shall not affect the overall status of this Agreement or the License
Term.

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-4-

 

	2.3	 	MRC shall supply all necessary personnel, administrative management, facilities, equipment
and supplies to enable timely completion of the Sponsored Research, including both of the MRC
Investigators, for the duration of the Sponsored Research Term. Reimbursement for MRC’s costs
and expenses for the Sponsored Research shall be provided only to the extent agreed to in
writing in the applicable Research Plan. Each Research Plan will be completed diligently by
MRC using best efforts in accordance with prevailing professional standards and all applicable
laws, regulations and MRC’s official policies. Should the MRC Investigators become
unavailable to complete any Research Plan, MRC and Omeros may agree on a substitute
investigator, and in the event that a mutually acceptable substitute is not available, either
party may terminate the Sponsored Research Term.
	 
	2.4	 	Within thirty (30) days of the end of each quarter of the Sponsored Research Term, MRC shall
submit a status report in written and electronic form (“Status Report”) summarizing the
results of the research completed during that quarter, except that annually within thirty (30)
days of the end of each year of the Sponsored Research Term or at such other point in time as
may be mutually agreed in writing, MRC shall submit a final status report in written and
electronic form (“Final Report”) detailing the results of the research completed during such
year of the Sponsored Research Term. Upon Omeros’ request, MRC shall complete all requested
corrections and make reasonable revisions to each Status Report and/or Final Report to place
it into a form suitable to meet Omeros’ objectives, including potential use of any Status
Report and/or any Final Report as part of any regulatory submissions.
	 
	2.5	 	In full and complete consideration for the Sponsored Research completed by MRC during the
Sponsored Research Term in accordance with the Research Plan(s), Omeros shall pay MRC a total
of [†] over the Sponsored Research Term in accordance with the annual schedule set forth in
Exhibit A, unless the Sponsored Research Terms is terminated earlier in accordance with the
provisions of this Section 2, in which case no further scheduled payments shall be payable, or
unless a change in the level of Sponsored Research work is agreed to in writing in subsequent
Research Plans, and subject to the following potential adjustment based on the British
national pay scale. The salary portion of the compensation amount payable during each year
includes a projected increase for changes in the British national standard pay scale, and
shall be adjusted up or down annually to reflect actual changes in the British national
standard pay scale. Compensation for each year of the Sponsored Research Term shall be
payable at the rate of twenty five percent (25%) of the annual amount per quarter, with a
first quarterly payment due and payable upon the start of the year, second and third quarterly
payments due and payable four and eight months, respectively, from the start of the year, and
a fourth quarterly payment due and payable upon the later of the end of the year or acceptance
of a Final Report for such year; provided, however, that no payment shall be due for any
quarter prior to the receipt and acceptance by Omeros of a Status Report or any Final Report,
as appropriate, for the respective quarter or year. All undisputed payments that have become
due and payable shall be paid within thirty (30) days of receipt of an invoice from MRC.

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-5-

 

	2.6	 	Omeros and the MRC Investigators shall collaborate on any proposed scientific publications of
Sponsored Research data and results, including a discussion of authorship and contents. MRC
shall furnish Omeros with copies of any publication or written or oral disclosure that is
proposed by MRC, including, without limitation, disclosures in papers or abstracts or at
research seminars, lectures, professional meetings, or poster sessions, at least sixty (60)
days prior to the proposed date for submission for publication or disclosure. During such
60-day period, Omeros shall have the right to review and comment on such publication for
accuracy and protection of confidential information. Additionally, upon Omeros’ written
request during the foregoing 60-day period, the proposed submission for publication or
disclosure shall be delayed until Omeros has completed the filing of patent applications
directed to information contained in such proposed publication or disclosure or based on
Omeros’ reasonable determination that publication should be delayed due to other business
considerations, but in no event will such delay exceed an additional ninety (90) days
following the initial 60-day period without MRC’s written consent, which consent shall not be
unreasonably withheld. Omeros shall have the right, in its sole discretion, to use, disclose,
disseminate and publish (with due acknowledgement of authorship) all data and results arising
out of the Sponsored Research for any and all purposes, including without limitation in and
for submissions to any regulatory agencies and in marketing any products including, but not
limited to, Licensed Products.
	 
	3	 	Ownership of Intellectual Property
	 
	3.1	 	All MRC IP shall remain owned or held by MRC to the same extent as would be the case were it
not for this Agreement.
	 
	3.2	 	All Omeros IP shall remain owned or held by Omeros to the same extent as would be the case
were it not for this Agreement.
	 
	3.3	 	All Joint IP shall be jointly owned by Omeros and MRC, i.e., Omeros and MRC each shall hold a
50% undivided joint ownership interest in all Joint IP, provided however that Omeros and MRC
recognize that third party collaborators such as Leicester may also have an ownership interest
in intellectual property included in the Joint IP, which third party ownership interest shall
not be impacted or determined by this Agreement.
	 
	4	 	Grant Of License
	 
	4.1	 	MRC hereby grants to Omeros for the term of this Agreement a royalty-bearing,
world-wide exclusive license in the MRC IP for the research, development, manufacture, use,
sale, offering for sale, distribution, exportation and importation of any and all products and
the practice of all methods within the MRC IP, including without limitation the exclusive
right to develop, manufacture, use, sell, offer for sale, distribute, export and import the
Licensed Products for all purposes including without limitation the research, development and
production of antibody or other MASP-2 inhibitor products.
	 
	4.2	 	MRC hereby grants to Omeros a fully paid-up, irrevocable, world-wide exclusive license
in and to MRC’s joint ownership interest in the Joint IP, for the manufacture, use, sale,

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-6-

 

offering for sale, distribution, exportation and importation of any and all products and the
practice of all methods encompassed by the Joint IP.

	4.3	 	Subject to publication approval and timing procedures consistent with Section 2.6
herein, MRC shall retain the right to use the MRC IP and the Joint IP for the purpose of
conducting non-commercial, academic research, including research sponsored by not-for-profit
entities, which shall not include the performance of research sponsored (directly or
indirectly) by or on behalf of any for-profit entity that is in direct competition with Omeros
in a technology, product or research tool that is the subject of the MRC IP or Joint IP.
	 
	4.4	 	Omeros shall have the right to grant sublicenses in the MRC IP and the Joint IP under
this Agreement subject, with respect to the MRC IP, to Omeros’ obligations to share sublicense
revenues as set forth in Section 5.
	 
	4.5	 	As part of the licenses granted to Omeros under Sections 4.1 and 4.2, MRC agrees to
transfer and provide and/or make available to Omeros upon request biological materials and any
other research materials and know-how encompassed by or included within the MRC IP and/or the
Joint IP to which MRC has appropriate rights and access, all such materials being provided on
the basis of Omeros reimbursing MRC for MRC’s actual cost in providing such materials but for
no additional consideration.
	 
	4.6	 	MRC also grants to Omeros a right of first refusal for an exclusive license in all of MRC’s
Intellectual Property Rights, for which Omeros has not already been granted a license
hereunder, and for which MRC has all necessary rights to offer such first refusal, and MRC
shall exert reasonable efforts to obtain such necessary rights, in (1) any commercially
applicable technology that arises during the Term of this Agreement and is directly related to
MASP-2 as more fully defined in the MRC IP and the Joint IP, and (2) any technology that has
been developed through the contribution of both Omeros and MRC after the Sponsored Research
Term.
	 
	5	 	Royalties and Sublicense Revenue
	 
	5.1	 	Omeros shall pay MRC on a quarterly basis a royalty for Licensed Products of [†] of that
portion of the Net License Proceeds realized during each respective quarter from Licensed
Products (the “Licensed Product Royalty”). Not withstanding the above, if the total royalties
owed by Omeros to all parties for Licensed Products, including without limitation the Licensed
Product Royalty payable to MRC, royalties payable to Leicester, [†] and any “stacking fee(s)”
or other royalties payable to third parties to develop, manufacture or commercialize the
Licensed Products (all together the “Total Royalty Percentage”), exceeds [†] of the Net
Licensed Proceeds for any quarter, then [†] of the difference between the Total Royalty
Percentage and [†] shall be deducted from the Licensed Product Royalty payable to MRC for such
quarter, provided, however that the Licensed Product Royalty for such quarter may not be
reduced by such deductions to less than [†].
	 
	5.2	 	Omeros shall pay MRC on a quarterly basis a share of that portion of the Net Sublicense

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-7-

 

Proceeds collected by Omeros on Licensed Products and collected by Omeros (“Sublicensed
Product Revenue Share”) from sublicensed third parties during each respective quarter, such
Sublicensed Product Revenue Share being either (a) [†] for any sublicenses in connection with
the Licensed Products granted hereunder prior to the earlier of (i) the establishment of MRC’s
clear, defensible, lawful and uncontested title in, or other mutually acceptable rights
relative to, [†] or (ii) the second year anniversary of the Effective Date of this Agreement,
or (b) [†] for any sublicenses in connection with the Licensed Products granted hereunder
thereafter.

	5.3	 	Omeros shall promptly provide MRC with a copy of all sublicenses granted by Omeros in the MRC
IP and/or the Joint IP under this Agreement.
	 
	5.4	 	Following receipt from the University of the results of all Sponsored Research and the
completion of all other necessary and beneficial research activities by Omeros and/or by
others to support appropriate government regulatory submissions by Omeros, [†] Omeros shall
use reasonable efforts, based on reasonable commercial prudence, to diligently develop and
introduce to the market one or more Licensed Products. Ongoing performance of research and/or
development efforts to generate or further advance one or more Licensed Products by Omeros,
internally at Omeros and/or under contract with MRC and/or a third party, shall be deemed to
be diligent efforts under this Section 5.4.
	 
	5.5	 	It is Omeros’ current intent to commercially develop and seek regulatory clearance to
clinically test and then market an inhibitor of MASP-2 activity following identification of
selective and high-affinity inhibitors of MASP-2 activity and demonstration of the therapeutic
benefit of such inhibitors in animal models, such identification and demonstration to be
completed collaboratively by MRC, Leicester and/or Omeros. Within three months of the
identification by Omeros of a Licensed Product that is determined by Omeros to be a viable and
optimal clinical development candidate, Omeros will submit a development plan to MRC that sets
forth Omeros’ planned activities and estimated timing for the development, regulatory approval
and market introduction of one or more Licensed Products. Assuming anticipated and adequate
progress is made in the Sponsored Research [†], Omeros anticipates the identification of an
initial potential candidate for a Licensed Product or Licensed Research Product that is a
potential clinical development candidate within two years of the commencement of the Sponsored
Research. The foregoing statements within this Section 5.5 and such development plan are or
will be provided as indications of current or future intentions only, and shall have no
binding effect on Omeros, nor shall it give rise to any right or obligation to either party,
and any modification, alteration or failure to meet any of these intentions shall have no
impact on this Agreement.
	 
	6	 	Payments
	 
	6.1	 	Quarterly royalty and sublicense revenue payments shall be made in British Pounds Sterling by
Omeros to MRC within sixty (60) days of the end of the quarter. Payments shall be computed
based on a conversion from any other denomination to British Pounds
Sterling for any revenues received or costs and expenses incurred by Omeros during the

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-8-

 

relevant quarter or other reporting period, as provided herein, using the prevailing
exchange rate in effect at the date and time that funds are transferred from Omeros’ account
to MRC’s account (in the case of payment by wire transfer) or at the date and time of
issuance of a check by Omeros (in the case of payment by check). Each quarterly payment
shall be accompanied by a report specifying (a) the source of the royalties itemized by
product and country, (b) any Omeros IP Legal Fees or Third Party License Fees that were
deducted from gross proceeds to determine Net License Proceeds or Net Sublicense Proceeds as
provided in Sections 1.9 or 1.10 of this Agreement, and (c) the total of all discounts,
returns, credits and commissions deducted from gross proceeds to determine Net License
Proceeds or Net Sublicense Proceeds as provided in Sections 1.9 or 1.10 of this Agreement.
Following the two-year anniversary of the Effective Date of this Agreement, in the event
that Omeros receives no such quarterly royalty and sublicense revenue in any given quarter,
it shall nevertheless submit a quarterly report to that effect to MRC within sixty (60) days
of the end of the quarter.

	6.2	 	MRC reserves the right to employ a certified public accountant to review and reconcile the
directly relevant accounting records and procedures of Omeros as they relate to the
determination of royalties or sublicense revenue fees under Section 5 herein during reasonable
business hours and no more than twice a year, and Omeros agrees to make available at Omeros’
place of business all such directly relevant accounting records for that purpose within 30
(thirty) days of written request by MRC. The cost of such review shall be borne by MRC,
unless it is found that Omeros under-paid a quarterly royalty or sublicense revenue fees for
any quarter by an amount of 10% (ten percent) or greater, in which case the cost of such
review shall be borne by Omeros.
	 
	6.3	 	In the event any royalty or sublicense revenue fee payments due under Section 5 herein are
not timely paid by Omeros, Omeros shall pay to MRC interest charges on such late payments at a
rate of [†] per annum.
	 
	6.4	 	Not withstanding anything to the contrary herein, Omeros shall have no obligation to pay any
royalties or sublicense revenue fees under Section 5 for any product based on any patent claim
that has been declared invalid or unenforceable by a court or governmental body of competent
jurisdiction or based on any patent claim that is not enforceable in the jurisdiction(s) where
such products are manufactured, used, sold, offered for sale, imported or distributed.
	 
	7	 	License Progress
	 
	7.1	 	Omeros shall on an annual basis, commencing on the one-year anniversary of the Effective Date
of this Agreement and annually thereafter, deliver to MRC within thirty (30) days after the
end of the respective year a written progress report detailing the status of Omeros’ efforts
to fund, patent, develop and commercialize Licensed Products.
	 
	8	 	Patent Prosecution
	 
	8.1	 	Omeros shall have the sole right at its discretion to apply for, prosecute and maintain
patents for inventions included within the MRC IP and the Joint IP (“Patent Filings”) in

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-9-

 

the name of the legally appropriate inventors and/or parties to this agreement and/or jointly with
third parties as may be legally appropriate, provided however that (a) Omeros shall bear all
cost and expense for all such Patent Filings, subject to the right to deduct Omeros IP Legal
Fees as set forth herein, (b) Omeros shall keep MRC timely informed of the progress of all
Patent Filings and timely provide MRC copies of all official documentation related to such
Patent Filings, and (c) Omeros shall exert commercially reasonable efforts to diligently
pursue all Patent Filings to issuance or final determination of unpatentability, provided
however that if Omeros determines at its sole discretion to not make Patent Filings for any
commercially significant inventions within the MRC IP or the Joint IP in any countries of
commercial significance, or abandons any Patent Filing prior to issuance or final
determination of unpatentability, Omeros shall give MRC advance written notice of such
determination, MRC shall have the right thereafter to elect upon written notice to Omeros to
pursue such Omeros abandoned Patent Filings at MRC’s sole expense (together with Leicester if
applicable), and such Omeros abandoned Patent Filings shall be excluded from the scope of the
licenses granted under this Agreement.

	8.2	 	MRC shall promptly provide written disclosure to Omeros of any inventions, improvements, or
applications included within the MRC IP or Joint IP conceived, developed, made or arising
before or during the term of this Agreement. MRC will provide all reasonable assistance,
including review of documents and the execution of all documents and causing MRC’s employees
to review and execute all documents, necessary to make, prosecute, maintain and enforce the
Patent Filings, all for no additional consideration but with reimbursement by Omeros of MRC’s
reasonable expenses for such assistance.
	 
	8.3	 	MRC shall promptly provide written disclosure to Omeros of any and all potentially material
prior art known prior to the Effective Date of this Agreement or that becomes known during the
License Term of this Agreement to any MRC employee that is associated with this Agreement, the
Sponsored Research, the MRC IP or the Joint IP.
	 
	9	 	Representations, Warranties and Other Obligations of Omeros
	 
	9.1	 	Omeros represents and warrants that it has the requisite corporate power and authority and
the legal right to enter into this Agreement and to perform its obligations hereunder.
	 
	9.2	 	Omeros has and will maintain reasonably adequate insurance coverage for employment practices
and general liability for all its activities under this Agreement. Prior to Omeros’ marketing
of any Licensed Product, or product encompassed by the Joint IP, or making any such products
available for use in any human patients, Omeros will obtain and maintain reasonably adequate
product liability insurance.
	 
	10	 	Representations, Warranties and Other Obligations of MRC
	 
	10.1	 	MRC has disclosed to Omeros the existence of the [†] and information as to the development of
the MRC IP, and MRC warrants that it has made reasonable efforts to ascertain the details of
such development and that it reasonably believes the same to be true. [†].

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-10-

 

	10.2	 	[†]
	 
	10.3	 	[†]
	 
	10.4	 	MRC represents and warrants, subject to the disclosure referred to in Section 10.1 with
respect [†] and to any rights owned by Leicester, that MRC is the owner of all other right,
title and interest in any and all inventions included within the MRC IP and the Joint IP made
or to be made wholly or jointly by MRC employees, including without limitation those made by
Mr. Willis and Dr. Reid, and shall cause Mr. Willis and Dr. Reid to each execute this
Agreement to confirm their agreement to be bound to the same extent as MRC with respect to all
relevant provisions of this Agreement.
	 
	10.5	 	Subject to [†] as discussed in Section 10.1 above and to any rights owned by Leicester, MRC
represents and warrants to Omeros that as far as it is aware, after having used reasonable
efforts to ascertain relevant facts and having formed a reasonable belief as to their truth,
it has the lawful right to grant the licenses conveyed under this Agreement, and that the MRC
IP and the Joint IP are unencumbered by any third party obligation, commitment, restriction or
license. [†]
	 
	10.6	 	[†] and any rights owned by Leicester, MRC warrants that it is not aware of any third party
rights that would be infringed as a result of Omeros’ fulfilling the terms of this Agreement.
	 
	10.7	 	MRC has and will maintain reasonably adequate insurance coverage for employment practices and
general liability for all its activities under this Agreement.
	 
	10.8	 	THE WARRANTIES SET FORTH EXPRESSLY IN THIS AGREEMENT ARE THE SOLE WARRANTIES
MADE BY EITHER PARTY TO THE OTHER AND THERE ARE NO OTHER WARRANTIES, REPRESENTATIONS OR
GUARANTEES OF ANY KIND WHATSOEVER, EITHER EXPRESS OR IMPLIED, REGARDING THE LICENSED PRODUCTS,
OR OTHER PRODUCTS, INCLUDING WITHOUT LIMITATION ANY EXPRESS OR IMPLIED WARRANTIES OF
MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE.
	 
	11	 	Confidentiality
	 
	11.1	 	MRC and Omeros hereby affirm and incorporate by reference the terms of the Mutual
Nondisclosure Agreement between the parties dated 9 May 2005 concerning the subject matter of
this Agreement, a copy of which is attached hereto as Exhibit B, except to the extent that the
terms of such nondisclosure agreement may conflict with the terms of this Agreement, in which
case the terms of this Agreement shall prevail. The parties further
agree that the mutual obligations of nondisclosure and non-use set forth in such Mutual
Nondisclosure Agreement shall subsist for a period of five (5) years after the termination
of this Agreement.

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-11-

 

	11.2	 	The terms of this Agreement shall be maintained in strict confidence by both MRC and Omeros,
and may not be disclosed by either party without the consent of the other party, except as may
be required under a court order or decree or as required to comply with any governmental law,
rule or regulation, and Omeros may disclose the terms of this Agreement to Omeros’ current and
potential employees, directors, consultants, shareholders, investors and corporate partners.
	 
	12	 	Indemnification
	 
	12.1	 	Each party (the “Indemnifying Party”) shall indemnify, hold harmless and defend the other
party and its employees, officers, directors, consultants and agents (the “Indemnified Party”)
against any and all claims, suits, losses, liabilities, damages, costs, fees, and expenses
(“Claims”) resulting from or arising directly out of the Indemnifying Party’s breach of any
representation, warranty or obligation under this Agreement, or the Indemnifying Party’s
exercise of the rights and obligations under this license or any sublicense, except that such
obligation to indemnify, hold harmless and defend shall not extend to any Claims to the extent
such Claims result from or arise directly from the negligence or misconduct of the Indemnified
Party. This indemnification does not include any indemnity in relation to product performance
or product liability, and furthermore does not include any incidental, consequential or
special damages.
	 
	13	 	Enforcement of Patent Rights
	 
	13.1	 	If either party learns of the infringement of any patent or other intellectual property right
included in the MRC IP or the Joint IP, that party shall promptly notify the other party of
such infringement and will provide the other party with all evidence of infringement in the
notifying party’s possession. Both parties shall use their best efforts in cooperation with
each other to terminate third party infringement without litigation.
	 
	13.2	 	Omeros shall have the sole right at its discretion to enforce the MRC IP and the Joint IP
against third party infringers, including the initiation of any civil action in Omeros’ name,
at Omeros’ sole cost, in which event any award, judgment, settlement or damages collected
shall belong solely to Omeros without duty to account to MRC. In the event that it is
necessary for Omeros to join MRC as a party to any such civil action, MRC shall join such
action for no additional compensation but at Omeros’ sole expense, and any award, judgment,
settlement or damages collected shall belong solely to Omeros without duty to account to MRC.
	 
	13.3	 	If Omeros unreasonably declines to initiate enforcement of the MRC IP and the Joint IP
against any third party infringer within ninety (90) days of a written demand from MRC to do
so, then MRC shall have the sole right at its discretion to enforce the MRC IP and the Joint
IP against such third party infringer, including the initiation of any civil action in
MRC’s name, at MRC’s sole cost, in which event any award, judgment, settlement or
damages collected shall belong solely to MRC without duty to account to Omeros.
	 
	14	 	Term and Termination

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-12-

 

	14.1	 	Unless terminated earlier as set forth in Section 14.2 or 14.3 herein below, this Agreement
shall subsist so long as there is any pending patent application within the MRC IP or the
Joint IP, any patent application in the process of being prepared for filing as agreed to by
Omeros and MRC or any valid and subsisting claim included within any patent, utility model or
inventor’s certificate within the MRC IP or the Joint IP (the “License Term”).
	 
	14.2	 	Omeros may terminate this Agreement by providing ninety (90) days advance written notice of
termination under this Section 14.2 to MRC, with or without cause, at any time [†].
	 
	14.3	 	Either party may terminate this Agreement at any time in the event that the other party (a) breaches any material obligation of this Agreement by first submitting written notice of
breach to the breaching party, which breach is not substantially cured within ninety (90)
days of the receipt of such notice, followed by written notice of termination then being
sent to the breaching party, or (b) declares or is adjudged by a court of competent
jurisdiction to be insolvent, bankrupt or in receivership, and such insolvency, bankruptcy
or receivership materially limits such party’s ability to perform its obligation under this
Agreement, excluding reorganizations entered into by such party with the consent of the
other party, which consent shall not be unreasonably withheld.
	 
	14.4	 	Omeros may at any time terminate its sponsorship of the Sponsored Research by providing
ninety (90) days advance written notice of termination under this Section 14.4 to MRC, for
cause as specified in Section 2.2 above or at any time due to failure to perform any Research
Plan or other breach of this Agreement by MRC, or without cause as specified in, and subject
to reimbursement of any severance fees that may be payable in accordance with, Section 2.2
above, in which event Sections 2.1 — 2.3 herein shall cease to be effective, and Sections 2.4
and 2.5 shall cease to be effective after all reports are provided and accepted and all
payments are made for Sponsored Research performed in accordance with the applicable Research
Plan prior to such notice, but the remainder of this Agreement shall continue in full force
and effect for the License Term, including all rights and obligations of both parties
hereunder. In the event of Omeros’ termination of its sponsorship of the Sponsored Research,
Omeros shall pay to MRC any and all non-cancelable sums reasonably incurred or committed to by
MRC prior to receipt of the notice of termination.
	 
	14.5	 	The provisions of Sections 2.6 (Publication), 3 (Ownership of Intellectual Property), 4.2 —
4.6 (License as applicable to Joint IP and right of first refusal), 8 (Patent Prosecution as
applicable to Joint IP), 9 and 10 (Representations and Warranties and Other Obligations), 11
(Confidentiality), 12 (Indemnification), 13 (Enforcement as applicable to Joint IP), 15 (Use
of Names) and 16 (Miscellaneous) above shall survive expiration or termination of
this Agreement for the period set forth therein or, if no period is set
forth therein, then indefinitely.
	 
	15	 	Use of Names
	 
	15.1	 	Nothing contained in this Agreement confers any right to either party to use in

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-13-

 

advertising, publicity, or other promotional activities any name, trade name, trademark, or other
designation of the other party hereto, and neither party shall make such use without the prior
written consent of the other party, provided however Omeros may through written, oral or
electronic communication disclose the existence of this Agreement and the names of MRC, Dr.
Reid, Mr. Willis and other of MRC’s employees and consultants to Omeros’ current and potential
employees, directors, consultants, shareholders, investors and corporate partners, and as
required to comply with any governmental law, rule or regulation.

	16	 	Miscellaneous
	 
	16.1	 	This Agreement including all appendices and exhibits attached thereto or incorporated by
reference therein constitutes the entire understanding of the parties hereto regarding the
subject matter of this Agreement, and no other representation, agreement, promise or
undertaking altering, modifying, taking from or adding to the terms of this Agreement shall
have any effect unless the same is reduced to writing and duly executed by the parties hereto.
In the event of any conflict between the main body of this Agreement and any attachments
thereto or documents incorporated by reference therein, the provisions of the main body of
this Agreement shall control.
	 
	16.2	 	Either party’s failure to enforce any provision of this Agreement will not be considered a
waiver of future enforcement of that or any other provision.
	 
	16.3	 	The laws of the state of Delaware, United States, without regard to its conflict-of-laws
provisions, shall govern this Agreement, its interpretation and its enforcement, and any
disputes arising out of or related to this Agreement.
	 
	16.4	 	The parties agree that, except as provided herein below, any claim or controversy arising out
of or relating to this Agreement or breach thereof shall be settled by arbitration in the
state of Delaware, United States, in accordance with the commercial rules of the American
Arbitration Association by a panel of three arbitrators, one selected by each party and the
third selected by the other two arbitrators. In any such arbitration proceeding, judgment
upon the award rendered by the arbitrator shall be final and binding upon the parties and may
be entered by either party in any court or forum of competent jurisdiction as provided herein
below. Notwithstanding the foregoing, both parties agree that any claims or controversies
concerning the validity or enforceability of any intellectual property, or the actual or
threatened disclosure or misuse of confidential information, may alternately be resolved by a
civil action in any court of competent jurisdiction as provided herein below, and both parties
further agree that each shall retain the right to seek injunctive relief in any court of
competent jurisdiction as provided herein
below to prevent a breach, threatened breach or continuing breach of this Agreement which
would cause irreparable injury (e.g., breaches of confidentiality or the like).
	 
	16.5	 	Any civil action prosecuted or instituted by either party as permitted herein above with
respect to any matters arising out of or related to this Agreement shall be brought in either
the United States District Court located in the state of Delaware, United States (if

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-14-

 

federal subject matter jurisdiction therein lies) or the Superior Court for the state of Delaware,
United States (if there is no subject matter jurisdiction in federal court), and each party
hereby consents to the jurisdiction and venue of such courts for such purposes.

	16.6	 	In the event that it is necessary for either party of this Agreement to take legal action to
enforce any of the terms, conditions or rights contained herein, or to defend any such action,
then the prevailing party in such action shall be entitled to recover from the other party all
reasonable attorneys fees, costs and expenses related to such legal action.
	 
	16.7	 	In the event that any portion of this Agreement is held invalid or unenforceable by a court
of law, that provision will be construed and reformed to permit enforcement of the provision
to the maximum extent permissible consistent with the parties’ original intent, and if such
construction is not possible, such provision shall be struck from this Agreement, and the
remainder of the Agreement shall remain in full force and effect as if such provision had
never been part of this Agreement.
	 
	16.8	 	For the purposes of this Agreement, the parties hereto are independent contractors, and
nothing in this Agreement shall be construed to place them in the relationship of partners,
principal and agent, employer/employee or joint venturers. Except as provided expressly
herein, each party agrees that it shall have no authority to bind or obligate the other party,
nor shall any party hold itself out as having such authority.
	 
	16.9	 	Neither party will be liable for failure or delay in performing any obligation under this
Agreement, or will be considered in breach of this Agreement, if such failure or delay is due
to a natural disaster or any cause reasonably beyond such party’s control, provided that such
party resumes performance as soon as possible following the end of the event that caused such
delay or failure of performance.
	 
	16.10	 	Neither party may assign this Agreement, or any obligation or right under this Agreement, in
whole or in part, without the other party’s prior written consent, which consent will not be
unreasonably withheld. This Section shall not be construed in any way to limit Omeros’ rights
to grant, at Omeros’ sole discretion, sublicenses hereunder. MRC consents to Omeros’
assignment of this Agreement in whole or in part in connection with the merger, consolidation
or transfer of all or substantially all of that portion of Omeros’ assets to which this
Agreement relates. Subject to these restrictions, this Agreement will be binding upon and
will inure to the benefit of the parties’ permitted successors and assignees.
	 
	16.11	 	Any notice required or permitted to be given hereunder by either party shall be in writing
and shall be (a) delivered personally, (b) sent by registered mail, return receipt requested,
postage prepaid, (c) sent by an internationally recognized courier service guaranteeing
next-day delivery, charges prepaid, or (d) delivered by facsimile (with the original
promptly sent by any of the foregoing manners) to the addresses or facsimile numbers of the
other party set forth below, or at such other addresses as may from time to time be
furnished by similar notice by either party. The effective date of any notice hereunder
shall be the date of receipt by the receiving party.

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-15-

 

	 	 	 
	If to Omeros:

	 	If to MRC:
	 
	 	 
	Omeros Corporation

	 	Medical Research Council
	1420 Fifth Avenue, Suite 2600

	 	20 Park Crescent
	Seattle, WA 98101

	 	London
	U.S.A.

	 	United Kingdom
	 

	 	W1B 1AL
	 
	 	 
	Attention: Gregory A. Demopulos, M.D.,

	 	Attention: Graham Wagner,
	                 Chairman & CEO

	 	Associate Director Licensing
	 

	 	and Agreements
	 
	 	 
	And copy to: Marcia S. Kelbon,
	 	 
	                      Patent & General Counsel
	 	 
	 
	 	 
	Fax: (206) 264.7856 

	 	Fax: +44.207.291.5325 
	Phone: (206) 623.4688 

	 	Phone: +44.207.291.5317 

	16.12	 	This Agreement may be executed in one or more counterparts, each of which will be considered
an original, and all of which will constitute the same instrument.

     IN WITNESS WHEREOF, Omeros and MRC have each acknowledged and accepted this Agreement by
causing it to have been signed by their respective duly authorized officials.

	 	 	 	 	 	 	 	 	 
	OMEROS CORPORATION	 	MEDICAL RESEARCH COUNCIL	 	 
	 
	 	 	 	 	 	 	 	 
	By:

	 	/s/ Gregory A. Demopulos
	 	By:
	 	/s/ Graham Wagner	 	 
	 

	 	 

	 	 
	 	 

	 	 
	 
	 	 	 	 	 	 	 	 
	Name:

	 	Gregory A. Demopulos, M.D.
	 	Name:
	 	Graham Wagner	 	 
	 

	 	 	 	 	 	 

	 	 
	 
	 	 	 	 	 	 	 	 
	Title:

	 	Chairman & CEO
	 	Title:
	 	Associate  Director  Licensing Agreements	 	 
	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	Date:

	 	11/16/07 
	 	Date:
	 	10th November 2005	 	 
	 
	 	 	 	 	 	 	 	 
	Fax:

	 	206.264.7856 
	 	Fax:
	 	+44 207 291 5325 	 	 

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-16-

 

The above Exclusive License and Sponsored Research Agreement is acknowledged by the
undersigned investigators, who agree to abide by the terms set forth therein.

	 	 	 	 	 	 	 	 	 
	PROFESSOR KENNETH B. M. REID	 	ANTHONY C. WILLIS	 	 
	 
	 	 	 	 	 	 	 	 
	Signed:

	 	 	 	Signed:	 	 	 	 
	 

	 	 

	 	 	 	 

	 	 
	Title:

	 	Director, MRC Immunochemistry Unit
	 	Title:	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	Date:

	 	 	 	Date:	 	 	 	 
	 

	 	 

	 	 	 	 

	 	 
	Fax:

	 	 	 	Fax:	 	 	 	 
	 

	 	 

	 	 	 	 

	 	 

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-17-

 

EXHIBIT A

To the Exclusive License and Sponsored Research Agreement

Between Omeros Corporation and the Medical Research Council

RESEARCH PLAN

Sponsor: Omeros Corporation

Research Institution: Medical Research Council (MRC)

Investigator: Dr. Ken Reid

Research Period: First year, commencing 1 November 2005

Research Aims and Activities

     Attachment 1 hereto sets for the research aims of the Sponsored Research program to be
completed during the first year. All activities to meet specific aim 1 are to be carried out by
MRC (“Dr. Reid’s lab”). Aims indicated as to be performed by Omeros or third parties, and all
animal models in specific aim 5, are provided herein for reference purposes only and shall not be
interpreted as any obligation on the part of Omeros or MRC. Specific aims and the corresponding
timeline may be modified as mutually agreed in writing by Dr. Ken Reid and Omeros.

Budget

     The total consideration to be paid to MRC for all Sponsored Research to be carried out during
the first through third years of the Sponsored Research Term, including without limitation full and
complete payment for all services, materials, facilities, overhead and indirect costs, but
excluding reimbursement for any legally required severance that may be payable as provided for is
Section 2.2 of this Agreement above, is as follows:

     Year 1 (1 November 2005 — 31 October 2006):

                 [†]

     Year 2 (1 November 2006 — 31 October 2007):

                 [†]

     Year 3 (1 November 2007 — 31 August 2008):

                 [†]

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-18-

 

EXHIBIT B

To the Exclusive License and Sponsored Research Agreement

Between Omeros Corporation and Medical Research Council

MUTUAL CONFIDENTIALITY AGREEMENT

OMEROS CORPORATION

MUTUAL CONFIDENTIALITY AGREEMENT

          This Confidentiality Agreement (“Agreement”) is entered into as of 9 May 2005 by and between
OMEROS CORPORATION (“Omeros”), 1420 FIFTH AVENUE, SUITE 2600, SEATTLE WA 98101 USA and MEDICAL
RESEARCH COUNCIL (“MRC”), 20 PARK CRESCENT, LONDON, UNITED KINGDOM, W1B 1AL.

     In the course of business negotiations and transactions between the parties hereto, either or
both parties and certain agents thereof (including without limitation, attorneys and consultants
representing the parties) may disclose certain confidential and proprietary information pertaining
to the mammalian gene and/or protein referred to as ‘mannan-binding lectin serine protease 2’ or
‘MASP-2’ as located, for example, on human chromosome 1p, the 19 kDa N-terminal CUB1-EGF domains of
MASP-2 referred to as MAp19, as well as patent applications, license and research agreements, and
research data concerning the same, for the sole purpose of evaluating a potential business
relationship and/or performing in accordance with an agreement between the parties (“Purpose”).
The parties want to provide for the protection of any such confidential and proprietary information
disclosed by one party (the “disclosing party”) to which the other party receiving the information
(the “recipient”) may have access. In consideration of continuing negotiations for or entering
into business transactions, the parties agree:

     1. Covenant Not to Disclose. For a period of at least five years from the date of last
disclosure hereunder, the recipient of any Confidential Information will not at any time disclose
or otherwise make known or available to any person, firm, corporation or other entity, or use for
its own account or for any purpose other than the Purpose, any Confidential Information disclosed
by the other party prior to or during the term of this Agreement, without the express prior written
consent of the disclosing party. The recipient shall utilize reasonable procedures to safeguard
Confidential Information, including releasing Confidential Information only to employees or
consultants who have agreed to abide by the recipient’s obligations hereunder on a “need-to-know”
basis.

     2. Confidential Information.

     2.1 For information disclosed by Omeros, “Confidential Information” means any and all
information relating to: (a) methods and pharmaceuticals or other agents to inhibit pain and
inflammation, cartilage loss, vasospasm, smooth muscle spasm, restenosis, or tumor cell adhesion,
and/or to accelerate recovery of joint motion and function, for use in surgical procedures
(including without limitation arthroscopic,

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-19-

 

			
	cardiovascular, urologic and general surgical procedures), other medical procedures, and/or
for treatment of cartilaginous disorders, which have been developed or are owned or held by Omeros;
(b) drug delivery systems and methods, which have been developed or are owned or held by Omeros;

(c) methods, antibodies and other agents and compositions for the inhibition of the complement
immune system, which have been developed or are owned or held by Omeros, and includes, without
limitation, research and development information, know-how, inventions, trade secrets, technical
data, formulae, treatment methods, license agreements, clinical trial design criteria, protocols,
investigators’ brochures, models, samples, processes, chemistry, manufacturing and controls
information, regulatory information, and any type of product development, business, marketing or
legal plans or strategies or financial information.

     For information disclosed by MRC, “Confidential Information” means any and all information
relating to MASP-2: methods, antibodies and other agents and compositions for the inhibition of the
complement immune system in relation to MASP-2, which have been developed or are owned or held by
MRC, and includes, without limitation, research and development information, know-how, inventions,
trade secrets, technical data, formulae, treatment methods, license agreements, models, samples,
processes, and any type of business, marketing or legal plans or strategies or financial
information.

     2.2 Confidential Information does not include information that the recipient can establish:

     2.2.1 is or becomes generally available to the public other than as a result of a disclosure
by the recipient;

     2.2.2 was in the possession of the recipient prior to its being furnished to the recipient
under this Agreement, provided that the source of such information was not known to the recipient
to be bound by a confidentiality agreement with, or other contractual, legal, or fiduciary
obligation of confidentiality to the disclosing party or any other party with respect to such
information;

     2.2.3 becomes available to the recipient on a non-confidential basis from a source other than
the disclosing party, provided that such source is not bound by a confidentiality agreement with,
or other contractual, legal, or fiduciary obligation of confidentiality to the disclosing party or
any other party with respect to such information; or

     2.2.4 was independently developed by the recipient without reference to the Confidential
Information, provided that such independent development can reasonably be proven by the recipient
by written records.

     2.3 If the recipient is required by order of a court of law, administrative agency, or other
governmental body to disclose any of the Confidential Information, the recipient will promptly
provide the disclosing party with reasonable advance written notice if at all possible to enable
the disclosing party the opportunity to seek a protective order or to otherwise prevent or limit
such legally required disclosure, will use reasonable efforts to cooperate with the disclosing
party to obtain such protection, and
will disclose only the legally required portion of the Confidential Information. Any such

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-20-

 

legally required disclosure will not relieve recipient from its obligations under this Agreement to
otherwise limit the disclosure and use of such information as Confidential Information.

     3. Limitations on Use. In further recognition of the value of Confidential Information, the
recipient acknowledges that it shall not engage in the reproduction of Confidential Information
through the techniques of “reverse engineering”. The recipient shall not make any use, either
directly or indirectly, of any Confidential Information to which the recipient has been, is or will
be exposed, except in the ordinary course of business pursuant to this Agreement for the Purpose or
as may be expressly authorized in a separate specific written agreement between the parties.
Nothing in this Agreement shall be construed as giving recipient any license or other right under
any intellectual property of the disclosing party. Neither party shall disclose the existence and
nature of this Agreement or the fact that it is evaluating the other party’s Information, except
that such disclosure to a party’s present and potential employees, consultants, officers,
directors, shareholders and investors is permitted, and neither party shall use the name of the
other party in any publicity or advertising without that party’s prior written approval.

     4. Return of Confidential Information. When requested by the disclosing party or at the
termination of the relationship giving rise to this Agreement, whichever first occurs, the
recipient immediately shall deliver all Confidential Information and all copies thereof in its
possession or in the possession of its employees, provided that the recipient’s legal counsel may
retain one archival copy of the Confidential Information solely for purposes of ensuring compliance
with this Agreement.

     5. Specific Performance. The parties acknowledge that (a) the covenants set forth in Sections
1, 3 and 4 are essential elements of the transactions contemplated in this Agreement and that, but
for the agreement to comply with such covenants, the parties would not have entered into such
transactions, and that the parties have consulted with, or have had the opportunity to consult
with, counsel and have been advised in all respects concerning the reasonableness of such covenants
as to scope and limit of time; (b) the disclosing party will not have any adequate remedy at law if
the recipient violates the terms of Sections 1, 3 and 4 fails to perform any of its other
obligations hereunder; and (c) the disclosing party shall have the right, in addition to any other
rights it may have, to obtain in any court of competent jurisdiction temporary, preliminary and
permanent injunctive relief to restrain any breach, threatened breach, or otherwise to specifically
enforce any of such covenants or any other obligations of the recipient if the recipient fails to
perform any of its obligations under this Agreement.

     6. Term. This Agreement and the obligations of nondisclosure and nonuse set forth herein
shall terminate five (5) years after the date of the last disclosure of Confidential Information
under this Agreement. Prior to termination of this Agreement, either party may deliver written
notice to the other party that it no longer wishes to receive Confidential Information under this
Agreement, after receipt of which any information subsequently sent in writing or orally disclosed
by either party shall be deemed non-confidential.

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-21-

 

     7. Miscellaneous. This Agreement shall be binding upon and inure to the benefit of the
parties’ successors and assigns. The waiver of any breach of any provision of this Agreement or
failure to enforce any provision hereof shall not operate or be construed as a waiver of any
subsequent breach by any party. The invalidity of all or any part of any section of this Agreement
shall not render invalid the remainder of this Agreement or the remainder of such section. If any
provision of this Agreement is so broad as to be unenforceable, such provision shall be interpreted
to be only so broad as is enforceable. In any litigation or disputes arising out of this
Agreement, the substantially prevailing party will be entitled to recover all reasonable costs and
attorneys’ fees, including costs and fees on appeal. The provisions of this Agreement shall not be
construed as limiting any rights or remedies that either party may otherwise have under the
applicable law.

     8. Governing Law. This Agreement shall be governed by and construed in accordance with the
laws of the State of Delaware.

     DATED as of 9 May 2005.

	 	 	 	 	 	 	 	 	 	 	 
	 	 	OMEROS CORPORATION	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	 

	 	By 	 	 	 	 	 	 	 	 
	 	 	 	   
	 
	 	 	 	 	 	 	 	 	 	 
	 

	 	 	 	 	Its 		 	 	 	 
	 	 	 	 	 	 	  
	 
	 	MEDICAL RESEARCH COUNCIL	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 
	 

	 	By 		 	 	 	 	 	 	 	 
	 	 	 	 	   
	 
	 	 	 	 	 	 	 	 	 	 	 
	 

	 	 	 	 	Its 		 	 	 	 
	 	 	 	 	 	 	  

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-22-exv10w33

Exhibit 10.33

FUNDING AGREEMENT

     This Funding Agreement (“Agreement”) is made as of December 18, 2006 (the
“Effective Date”) by and between The Stanley Medical Research Institute, a 501(c)(3)
corporation organized under the laws of Connecticut and having a place of business at 8401
Connecticut Avenue, Suite 200 Chevy Chase, MD 20815 (“SMRI”), and Omeros Corporation, a
corporation organized under the laws of Washington State and having its principal place of business
at 1420 Fifth Avenue, Suite 2600 Seattle, WA 98101 (“Omeros”) (together with SMRI, the
“Parties” and each, a “Party”).

     WHEREAS, Omeros has a program for the development of a PDE10 inhibitor as a therapeutic
candidate for the treatment of schizophrenia and/or other neuropsychiatric disorders; and

     WHEREAS, SMRI desires to fund, with a combination of grant and equity financing, certain
development work with respect to Omeros’ PDE10 program on the terms and conditions set forth
herein.

     NOW, THEREFORE, in consideration of the mutual covenants and promises herein contained, the
Parties agree as follows:

1 Certain Definitions.

	1.1	 	Defined Terms. Following is a list of the defined terms used in this Agreement and,
where applicable, the section references where they are defined.

     “Administrative Expenses” shall have the meaning set forth on Exhibit A.

     “Affiliate” means, with respect to a particular Party, a person, corporation,
partnership, or other entity that controls, is controlled by or is under common control with such
Party. For the
purposes of the definition, the word “control” (including, with correlative meaning, the terms

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

 

“controlled by” or “under common control with”) means the actual power, either directly or
indirectly through one or more intermediaries, to direct or cause the direction of the management
and policies of such entity, whether by the ownership of at least fifty percent (50%) of the voting
stock of such entity, or by contract or otherwise.

     “Combination Product” means any product containing both (i) the Product, and (ii) one
or more other therapeutically active ingredients.

     “Commercialization Expenses” shall have the meaning set forth on Exhibit A.

     “Commercially Reasonable Efforts” shall mean the application of a material level of
effort, expertise and resources that is generally consistent with industry standards for companies
of Omeros’ size, capitalization and development stage to, as appropriate, research, develop and
commercialize a Product where such research, development and commercialization are technically
feasible, devoting the same degree of attention and diligence to such efforts that is substantially
and materially consistent with industry standards for companies of Omeros’ size, capitalization and
development stage and for products at a comparable stage of development, with the objective of
launching Products in one or more countries as soon as commercially practicable.

     “Commercial Sale” means sale of the Product by Omeros, its Affiliates or licensees,
following Regulatory Approval. Sales for test marketing, sampling, promotional uses, clinical
trial purposes or compassionate or similar use shall not be considered to constitute a Commercial
Sale.

     “Confidentiality Agreement” shall have the meaning set forth in Section 3.2.

     “Cost of Goods Sold”. shall have the meaning set forth on Exhibit A.

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-2-

 

     “Currency Adjustments” shall have the meaning set forth on Exhibit A.

     “Direct Investment” means all internal and external expenses directly attributable to
the Program, including, without limitation, all related research and development costs (including,
without limitation, clinical, regulatory and Patents costs), program acquisition costs, FTE costs,
dedicated equipment and laboratory supplies, and laboratory space.

     “Early Royalties” shall have the meaning set forth in Section 2.6.

     “FDA” means the United States Food and Drug Administration, or any successor entity.

     “First Commercial Sale” means the first Commercial Sale to a third party.

     “FTE” shall mean the equivalent of a full-time employee’s working days over a twelve
(12) month period (including normal vacations, sick days and holidays). The portion of an FTE
devoted by an employee to a Program over a year shall be determined by dividing the number of full
days during any twelve (12)-month period devoted by such employee to the program by the total
number of working days during the twelve (12)-month period.

     “Grant Funds” shall mean grant funds paid to Omeros under the Agreement by SMRI.

     “Intellectual Property Rights” means all of the following, whether U.S. or non-U.S.:
(a) Patents; (b) trademarks, service marks, trade dress, logos, tradenames, service names,
domain names, Internet websites and corporate names and registrations and applications for
registration thereof; (c) copyrights, copyrightable works, and registrations and applications for
registration thereof, including copyrights relating to computer programs; (d) mask works and
registrations and applications for registration thereof; (e) trade secrets; (f) computer programs;
(g) biological

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-3-

 

materials, bioassays, cell lines, clones, molecules, protocols, reagents, experiments, lab
results, tests and all other tangible or intangible proprietary information; and (h) other
proprietary rights whether or not relating to any of the foregoing (including without limitation
associated goodwill and remedies against infringements thereof and rights of protection of an
interest therein under the laws of all jurisdictions).

     “Interruption” shall occur if at any time before the First Commercial Sale of a
Product, Omeros, its Affiliates, licensees, sublicensees, transferees and/or successors, all cease
to conduct, or to cause to have conducted Commercially Reasonable Efforts with respect to the
research, development and/or commercialization of a Product, including without limitation
regulatory, patent and business partnering activities concerning a Product, for a period of [†]
consecutive days; provided, however, that any cessation of such activities due to a regulatory
process, availability of compounds, materials or necessary processes, the procurement of
Intellectual Property Rights, any dispute or legal proceeding concerning third party Intellectual
Property Rights that are necessary to the research, development and/or commercialization of a
Product, or any other material factor not reasonably within Omeros’, its Affiliates’, licensees’,
transferees’ and/or successors’ control (e.g., strikes, terrorism, natural disasters, war), that
renders the research, development and/or commercialization impracticable shall be excused and shall
not constitute an Interruption.

     “Interruption License” shall have the meaning set forth in Section 3.1.4.

     “IPO” shall have the meaning set forth in Section 2.3.1.

     “JPAC” shall have the meaning set forth in Section 3.7.1.

     “JPAC Reports” shall have the meaning set forth in Section 3.7.1.

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-4-

 

     “Milestone” shall have the meaning set forth in Section 2.2.2.

     “Net Income” shall have the meaning set forth on Exhibit A.

     “Net Program Conveyance Proceeds” shall have the meaning set forth in Section 2.6.

     “Net Sales” shall have the meaning set forth in on Exhibit A.

     “Omeros Designee” shall have the meaning set forth in Section 3.7.1.

     “Patents” means inventions, patents, patent applications (including provisional
applications), patent disclosures and all related continuation, continuation-in-part, divisional,
reissue, re-examination, utility, model, certificate of invention and design patents,
registrations, applications for registrations and any term extension or other governmental action
which provides rights beyond the original expiration date of any of the foregoing.

     “PDE10” means phosphodiesterase 10.

     “Phase 2 Clinical Trial” means a human clinical trial evaluating the efficacy and
safety of the Product in any country that would satisfy the requirements of 21 CFR §312.21(b).

     “Phase 3 Clinical Trial” means a human clinical trial evaluating the efficacy and
safety of the Product in any country that would satisfy the requirements of 21 CFR §312.21(c).

     “Product” means any therapeutic product developed under this Agreement that inhibits
or modulates PDE10.

     “Program” means research and development activities, including without limitation
clinical and regulatory activities, relating to PDE10 and the development of the Product.

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-5-

 

     “Program IP” shall have the meaning set forth in Section 3.1.1.

     “Program Conveyance” shall have the meaning set forth in Section 2.6.

     “Regulatory Approval” means an approval, if any, by the health regulatory authority in
a given country or jurisdiction, required for the sale/marketing and, if necessary, pricing of the
Product for use in humans for a given indication.

     “Royalties” shall have the meaning set forth in Section 2.5.

     “SEC” means the United States Securities and Exchange Commission, or any successor
entity.

     “Series E Shares” shall have the meaning set forth in Section 2.2.1(b).

     “SMRI Designee” shall have the meaning set forth in Section 3.7.1.

     “SMRI Royalty Share” shall have the meaning set forth in Section 2.5.

     “SPA” shall have the meaning set forth in Section 2.2.1(b).

     “Third Party Expenses” shall have the meaning set forth in Section 5.9.

     “Third Party Royalties” shall have the meaning set forth on Exhibit A.

2 The Funding.

2.1 The Funds. SMRI shall provide Omeros with up to nine million dollars ($9,000,000) of
combined equity and grant funding set forth below.

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-6-

 

2.2 Disbursement of Funds to Omeros.

2.2.1 Upfront Payment. Upon execution of this Agreement, SMRI shall:

     (a) make a cash payment of $1.3M to Omeros as Grant Funds; and

     (b) purchase $1.3M of Omeros Series E preferred stock (the “Series E Shares”) at a
purchase price per share of $5.00, pursuant to the Series E Preferred Stock Purchase Agreement
dated March 16, 2004 as attached hereto as Exhibit B including the most recent Addendum
thereto substantially in the form included in Exhibit B (collectively the “SPA”).
Upon the purchase of such Series E Shares, SMRI shall also execute and become a party to that
certain Amended and Restated Investors’ Rights Agreement, attached hereto as Exhibit C, by
and among Omeros and certain investors named therein.

2.2.2 Milestones. In addition to the Upfront Payment set forth above, SMRI may at its
option make the following additional payments: (i) further equity investments in Omeros in
accordance with Section 2.3 below; and (ii) further grant funding upon achievement of the
following milestones (the “Milestones”).

	 	 	 	 	 	 	 
	Stage	 	Payment Milestone	 	Equity	 	Grant Funding
	Preclinical Development

	 	Upon achievement of a
Product candidate that
meets the following
preclinical criteria:
	 	Up to $1.2MM
	 	Up to $1.9MM
	 

	 	[†]	 	 	 	 
	Phase 1 Clinical Program

	 	Upon filing of
Investigational New Drug
Application with the FDA
	 	Up to $0.6MM
	 	Up to $2.7MM
	Totals (including Upfront Equity and Grant Payments)	 	Up to
$3.1MM	 	Up to
$5.9MM

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-7-

 

2.2.3 Achievement of Milestones. Upon achievement of a Milestone, Omeros shall notify SMRI
as set forth in Section 3.7.2 below. SMRI and Omeros shall meet promptly, in person or by
teleconference, in order to determine whether SMRI will make and Omeros will accept a further
equity investment plus associated grant funding with respect to such Milestone up to the amounts
set forth in Section 2.2.2 as may be mutually agreed. SMRI shall make any agreed upon
further payments of further equity investment plus associated grant funding to Omeros within thirty
(30) days of determination of the JPAC that a Milestone has been satisfied and achieved. It is the
intent of the Parties that the total equity investment(s) made by SMRI under this Agreement equal
34-35% of the total funding (including equity investments plus Grant Funds) provided by SMRI to
Omeros under this Agreement.

2.3 Equity for Milestone Payments.

2.3.1 Terms of Investment. The equity purchased by SMRI for the Milestones shall be either
(i) Series E Shares in accordance with the SPA, if purchased prior to Omeros’ initial public
offering (“IPO”) or (ii) unregistered common stock of Omeros, registrable within 90 days of
issuance and priced at the average closing ask price for Omeros’ common stock for the five trading
days preceding the closing of the equity investment, less a discount of 0 to 10%, such discount to
be mutually agreed by Omeros and SMRI, if purchased after the IPO. Omeros shall provide SMRI
written notice in the event that it files a Form S-1 with the United States Securities and Exchange
Commission (the “SEC”) within ten (10) days following such filing.

2.3.2 Option to Purchase Equity Early. During a thirty (30)-day period following receipt
by SMRI of notification of Omeros’ filing of Form S-1 with the SEC, SMRI shall have the right to
purchase Series E Shares at a purchase price of five dollars ($5.00) per share, provided, such
equity

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-8-

 

investment is made concurrent with payment by SMRI to Omeros of the corresponding grant funding.

2.4 Additional Funding. SMRI may optionally purchase additional equity in Omeros and/or
provide Omeros with additional grant funding, subject to the mutual agreement of the Parties. Such
additional investment may be in an amount equal to as much as [†] of the total costs associated
with the Phase 2 Clinical Trials and Phase 3 Clinical Trials for the Product candidate. The
parties agree to negotiate in good faith concerning such additional funding; provided, however,
SMRI shall not be obligated to make such additional equity investment or pay such additional grant
funding, and Omeros shall not be obligated to sell such additional equity or accept such additional
grant funding.

2.5 SMRI Royalty. In consideration of SMRI’s payment of the Grant Funds and its agreement
to license Program IP to Omeros, except as provided in Section 2.6, beginning the first
calendar year after the First Commercial Sale occurs, Omeros shall pay SMRI royalties
(“Royalties”) equal to [†] of Omeros’ Net Income in any given year (the “SMRI Royalty
Share”) subject to maximum payment amounts as follows:

	 	 	 
	 	 	Royalty Equal to the
	 	 	following multiple of
	Royalties	 	Grant Funds
	1. For any portion of Grant Funds paid within [†]
of date of receipt by Omeros of such portion of the
Grant Funds

	 	[†]
	 
	 	 
	2. For any portion of the Grant Funds remaining
after payments in subparagraph 1 above that are
repaid within [†] of date of receipt by Omeros of
such portion of the Grant Funds

	 	[†]
	 
	 	 
	3. For any portion of the Grant Funds remaining
after payment in subparagraph 2 above that are
repaid within [†] of the date of receipt by Omeros
of such portion of the Grant Funds

	 	[†]

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-9-

 

     Omeros shall pay the SMRI Royalty Share within sixty (60) days of the end of each calendar
quarter. Omeros may prepay the royalty set forth in the table above, at any time, without penalty
or premium, at its option. If there are no Commercial Sales of the Product, or if Omeros
terminates the Program for any reason, Omeros shall have no obligation to pay Royalties thereafter.

     SMRI shall have the right to audit Omeros’ financial statements to the extent directly
relevant to the computation of Omeros’ Net Income and the SMRI Royalty, at reasonable times
following advance request and no more frequently that once per year. SMRI shall bear the fees and
expenses in connection with any such audit, except that if an error in Omeros’ Net Income of more
than five percent (5%) is discovered from any such audit, then Omeros shall bear the reasonable
costs of such audit.

2.6 Assignment and Sublicensing. In the event that Omeros conveys to a third party all or
substantially all of its rights to and title in the Program, by assignment, sale, exclusive
license/sublicense or other conveyance, including all rights related to the Product and the Program
IP (a “Program Conveyance”) without reservation of any commercialization right, separate
from and independently of the assignment, sale, exclusive license/sublicense or other conveyance of
any other of Omeros’ programs or assets, for a net amount after deducting (a) all of Omeros’ costs
associated with such sale and (b) Omeros’ Direct Investment (“Net Program Conveyance
Proceeds”), that exceeds Omeros’ Direct Investment, Omeros shall make early payment of the SMRI
Royalty up to a maximum amount equal to [†] of the total of the Net Program Conveyance Proceeds
(the “Early Royalties”). The Early Royalties shall not exceed the total of the Grant Funds
multiplied by the applicable multiple set forth in Section 2.5. The obligation to pay
royalties remaining after any Early Royalty payment in accordance with the preceding sentence of
this Section 2.6 shall be

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-10-

 

assumed by any third party assignee or other successor of title
to the Program as provided in
Sections 5.2 and 5.3, and shall be retained by Omeros in the case of any license/sublicense of the
Program.

3 Intellectual Property; Confidentiality; Indemnification; Covenants.

3.1 Intellectual Property.

3.1.1 Ownership. All Intellectual Property Rights created, conceived or reduced to
practice in connection with the Program and during the course of this Agreement by Omeros and/or by
SMRI (the “Program IP”), as well as all of Omeros’ pre-existing Intellectual Property
Rights related to PDE10, shall be owned by Omeros. SMRI shall, and hereby does, grant an exclusive
license to Omeros to any and all of SMRI’s other right, title and interest in and related to any
Program IP (and shall require and cause SMRI’s employees and contractors to assign all of their
rights, title and interest in and to any Program IP to SMRI. Further, SMRI shall execute and
deliver (and shall require and cause its employees and contractors to execute and deliver), upon
the request of Omeros, any assignments, powers of attorney, declarations or other instruments, and
take any actions, as may be necessary or desirable to confirm Omeros’ ownership of the Program IP
and to assist Omeros in applying for, prosecuting, maintaining and enforcing the Program IP
including any Patent included therein.

3.1.2 No Rights in Omeros’ Intellectual Property. Except as provided in Section
3.1.4, there shall be no license, express or implied, granted to SMRI in connection with this
Agreement to any of Omeros’ Intellectual Property, including without limitation, the Program IP.

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-11-

 

3.1.3 Abandonment. Notwithstanding any contrary provision contained herein, prior to
Omeros (or any Affiliate, licensee, sublicensee, transferee or successor of Omeros) abandoning any
Patent or
patent application related to the Program IP (including abandonment for failure to pay any required
fees), Omeros shall promptly notify SMRI, or cause SMRI to be notified, of such pending
abandonment, whereupon SMRI shall have the right and opportunity to assume title to the applicable
Patent and/or patent application and to maintain the issued patent or continue the prosecution of
the patent application at SMRI’s own expense. Omeros hereby agrees to exercise its good faith
efforts to obtain such consents, on SMRI’s behalf, as may be necessary, advisable and/or
appropriate for SMRI to exercise its rights under this Section 3.1.3. Thereafter, prior to
SMRI (or any Affiliate, licensee, sublicensee, transferee or successor of SMRI) abandoning any such
assumed Patent or patent application related to the Program and any Product, Omeros shall have the
right and opportunity to reassume title to such assumed Patent or patent application under the same
conditions as provided for SMRI above in this subsection 3.1.3.

3.1.4 Interruption License. Effective as of the Effective Date, Omeros hereby grants to
SMRI with respect to the Program the following option to take a license (the “Interruption
License”), which shall become exercisable by SMRI in the event of an Interruption:

     (a) An exclusive (even as to Omeros except for research purposes) worldwide license, with the
right to sublicense, under the Program IP to develop, manufacture, have manufactured, use, sell,
offer to sell and import Products, together with a nonexclusive worldwide license, with the right
to sublicense, to any other Intellectual Property Right in the Program solely to the extent
necessary for SMRI to develop, manufacture, have manufactured, use, sell, offer to sell and import
Products.

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-12-

 

     (b) In the event that Omeros transfers all or substantially all of its rights and obligations
to develop and commercialize a Product to a third party by virtue of a Program Conveyance, Omeros
shall use reasonable good faith efforts to obtain reversion rights from the third party. The time
required for such rights to revert to Omeros shall be excused and shall not constitute an
Interruption. Upon reversion to Omeros of such rights in the Product, the Interruption License
shall again become exercisable by SMRI in the event of an Interruption, in which case such
reversion rights shall flow to the benefit of SMRI. Except for such reversion rights that Omeros
might obtain from any third party, such third party shall not be subject to the obligations of the
Interruption License.

     (c) The Interruption License shall be deemed to constitute intellectual property as defined in
Section 365(n) of the U.S. Bankruptcy Code. Omeros agrees that SMRI, as a licensee of such rights,
shall retain and may exercise all of its rights and elections under the U.S. Bankruptcy Code;
provided, however, that nothing in this Agreement shall be deemed to constitute a
present exercise of such rights and elections.

     (d) In connection with this Section 3.1.4, Omeros shall deliver to SMRI, within thirty
(30) days of the occurrence of an Interruption, all materials and data generated in the performance
of the Program, and all other materials and data that Omeros may own and/or control that are
required by SMRI to use and practice and applicable technology.

     (e) In the event that the Interruption License becomes effective, in lieu of any other
royalties pursuant to this Agreement (other than royalties or payments under Sections 2.5 and 2.6
previously paid by Omeros to SMRI in accordance with this Agreement), the Parties shall share
equally any amount SMRI receives with respect to the Program or any Product (including amounts
received in connection with sublicenses of the Interruption License), provided that, SMRI’s share

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-13-

 

shall increase and Omeros’ share shall decrease by [†] SMRI spends in addition to the Grant Funds
and equity investment pursuant to this Agreement with respect to the research, development and/or
commercialization of the Product after the effective date of the Interruption License, except that,
in no event shall Omeros’ share decrease below [†]. Thus, for example, if SMRI’s expenditures
after the effective date of the Interruption License are [†], SMRI’s share will increase to [†] and
Omeros’ share will decrease to [†].

3.2 Confidentiality; Use of Names. The terms and existence of this Agreement, as well as
any information disclosed to SMRI by Omeros in connection with this Agreement and the Program,
including without limitation the Program reporting pursuant to Section 3.7, shall be considered
“Confidential Information” and subject to, and governed by, the terms of that certain
Confidentiality Agreement by and between SMRI and Omeros dated August 8, 2006 (the
“Confidentiality Agreement”); provided, however, that each party shall be permitted to
disclose the terms and existence of this Agreement to its respective employees, officers,
directors, consultants and professional advisors, and Omeros shall be permitted to disclose the
terms and existence of this Agreement to its current and prospective shareholders, investors and
commercial partners. Except as permitted above in this Section 3.2 with respect to disclosure of
the existence and terms of this Agreement, neither party shall use the other party’s name without
the other party’s written consent, including without limitation for any promotional or marketing
purposes.

3.3 Indemnification. Omeros agrees to indemnify, defend, and hold SMRI harmless from and
against any liability, losses, damages, and expense (including reasonable attorney’s fees and
costs) arising from any third party claim, action or proceeding to the extent shown by a court of
competent jurisdiction to have arisen from: (a) injuries to persons or damages which occur on
Omeros’

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-14-

 

premises, (b) the negligence or intentional misconduct of Omeros, except in each of (a) and
(b), to the extent caused by the negligence or intentional misconduct of SMRI, and (c) the knowing
infringement of any patent by Omeros. In the event of an Interruption and exercise by SMRI of its
option to take an Interruption License under Section 3.1.4 herein, SMRI agrees to indemnify,
defend,
and hold Omeros harmless from and against any liability, losses, damages, and expense (including
reasonable attorney’s fees and costs) arising from any third party claim, action or proceeding to
the extent shown by a court of competent jurisdiction to have arisen from: (a) injuries to persons
or damages which occur on SMRI’s premises, (b) the negligence or intentional misconduct of SMRI,
except in each of (a) and (b), to the extent caused by the negligence or intentional misconduct of
Omeros, and (c) the knowing infringement of any patent by SMRI.

3.4 Insurance. Omeros shall maintain at its own expense, with a reputable insurance
carrier reasonably acceptable to SMRI, coverage for Omeros, its Affiliates, and their respective
employees written on a per occurrence basis, commensurate with a reasonable assessment of the risks
associated with the research efforts being conducted by Omeros, which insurance will name SMRI as
an additional insured. Such insurance shall include without limitation errors and omissions
insurance encompassing claims relating to the performance and lack of performance of Omeros’
obligations under this Agreement and comprehensive general liability insurance for claims relating
to the performance and lack of performance of Omeros’ obligations under this Agreement and
comprehensive general liability insurance for claims for damages arising from bodily injury
(including death) and property damages arising out of acts or omissions of an Omeros Party which
will be specifically endorsed to cover Omeros’ indemnification obligations under Section 3.3.
Maintenance of such insurance coverage will not relieve Omeros of any responsibility under this
Agreement for damages in excess of insurance limits or otherwise. On or prior to the Effective
Date,

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-15-

 

Omeros shall provide SMRI with an insurance certificate from the insurer(s) evidencing each
insurance coverage and the insurer’s agreement to notify SMRI at least sixty (60) days in advance
of any cancellation or modification of such insurance coverage. At its request, SMRI may review
Omeros’ insurance coverage with relevant Omeros officials from time to time.

3.5 DISCLAIMER OF WARRANTY; LIMITATION OF LIABILITY. THE PARTIES RECOGNIZE THAT RESEARCH
AND DEVELOPMENT IS INHERENTLY UNCERTAIN AND NONE OF THE PARTIES HERETO MAKE ANY REPRESENTATIONS,
WARRANTIES, OR GUARANTIES OF ANY KIND WITH RESPECT TO THE SUCCESS OF THE PROGRAM OR THE PRODUCT.
EXCEPT WITH RESPECT TO BREACHES OF THE CONFIDENTIALITY AGREEMENT OR THE INTELLECTUAL PROPERTY
PROVISIONS OF SECTION 3.1 ABOVE, IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER PARTY
HERETO, OR TO ANY THIRD PARTY, FOR ANY LIABILITY, DAMAGES, OR EXPENSE INCLUDING SPECIAL, DIRECT,
INDIRECT, CONSEQUENTIAL DAMAGES OR OTHER ECONOMIC LOSS IN CONNECTION WITH THIS AGREEMENT.

3.6 Operation of the Program.

3.6.1 General. Subject to Section 3.6.2 below, Omeros shall (i) use Commercially
Reasonable Efforts to achieve the milestones set forth herein and ultimately commercialize a
Product, (ii) use the Grant Funds furnished by SMRI solely for the Program in Omeros’ sole
discretion; provided that, it is Omeros’ intention to expend amounts on the Program that exceed the
Grant Funds and amounts of SMRI’s equity investment under this Agreement.

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-16-

 

3.6.2 Personnel; Outsourcing. Omeros will maintain an in-house chemist to supervise, and
consulting chemists to assist with, the Program, which chemists shall be reasonably acceptable to
and approved by SMRI, such approval not to be unreasonably conditioned, withheld or delayed. SMRI
agrees that [†], Omeros’ Senior Group Leader, Medicinal Chemistry, with support from consultants
[†], are acceptable to SMRI for purposes of this Section 3.6.2. Further, SMRI shall have
the right to approve contract research organizations and consultants selected for outsourced
chemistry work, such approval not to be unreasonably conditioned, withheld or delayed.

3.7 Joint Program Advisory Committee; Program Reporting.

3.7.1 Composition and Purposes. During the term of the Research Program, a Joint Program Advisory
Committee (“JPAC”) shall facilitate communication between the Parties, and make
recommendations, with respect to the Program. The JPAC shall consist of four (4) members, two (2)
of whom shall be designated by Omeros (the “Omeros Designees”), and two (2) of whom
shall be designated by SMRI (the “SMRI Designees”). Each party (a) shall select a
Program Coordinator from among its designees to the JPAC (who may be changed at any time or from
time to time by such Party), and (b) may change any of its designees to the JPAC at any time or
from time to time. The Program Coordinator of Omeros shall serve as the Chairperson of the JPAC.
The initial Omeros Designees and the initial SMRI Designees shall be identified by the respective
Parties within thirty (30) days of the execution of this Agreement.

     Without limiting the generality of the foregoing, the JPAC shall:

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-17-

 

     (a) consider, review, reevaluate and discuss the research plan, evaluate any proposed
revisions to the research plan, and give its recommendations regarding any proposed amendments to
the research plan;

     (ii) monitor the progress of the Program, and make recommendations to Omeros’ research team as
needed on next steps to implement the Program;

     (iii) determine whether the Milestones have been satisfied and achieved; and

     (iv) provide periodic meeting reports on the status of the Program to SMRI (the “JPAC
Reports”), which JPAC Reports shall not include the chemical structure of any Products or
Product candidates in recognition of the serious harm to the Program and Omeros that could result
from the disclosure of such structures.

3.7.2 Meetings. The JPAC shall meet no less frequently than once in each six (6) month
period during the Research Program; provided, however, that the JPAC shall meet
more frequently if requested by either Program Coordinator. The first meeting of the JPAC shall be
held within ninety (90) days of the Effective Date. Meetings of the JPAC shall be held at such
times and locations as may be mutually agreed upon by the Program Coordinators, which times and
locations shall be communicated in writing (including, without limitation, by email) to the other
members of the JPAC with reasonable advance notice of the meeting. Members of the JPAC may attend
each meeting either in person or by means of telephone or other telecommunications device that
allows all participants to hear and speak at such meeting simultaneously. At least ten (10)
business days prior to each meeting, Omeros shall deliver (including by email) to SMRI a written
report detailing the progress made on the Program since the last meeting of the JPAC. Within
twenty (20) days after the

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-18-

 

date of each meeting, the Omeros Designees shall prepare and deliver
(including by email) to the SMRI Designees written minutes of such meeting setting forth in detail
all discussions and/or recommendations of the JPAC made at such meeting, which such minutes shall
be subject to the prior approval of SMRI’s Program Coordinator, but which minutes shall not include
the chemical structure of any Products or Product candidates.

3.7.3 Expenses. Each Party shall pay its own expenses (including travel and lodging
expenses) incurred in connection with its participation on the JPAC.

3.7.4 Reporting. After the completion of the Program and until the First Commercial Sale,
Omeros shall report in writing on an annual basis on the progress of the Program.

3.8 Board. At Omeros’ request and discretion, [†], will join Omeros’ Board of Directors.
It is understood that, if [†] joins Omeros’ Board, he would attend some Board Meetings by
videoconference or teleconference. Omeros would provide [†] with Directors’ and Officers’
liability coverage and an indemnification agreement (attached hereto as Exhibit D)
consistent with coverage and indemnification provided to other members of Omeros’ Board. Such
coverage and/or indemnification agreement may be amended in connection with Omeros’ IPO. In
keeping with legal requirements for Washington corporations, [†] will be subject to the normal
fiduciary and confidentiality obligations of a board member. It is anticipated that Omeros will
keep SMRI informed of the progress of the Program through the JPAC Reports.

4 Term and Termination.

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-19-

 

4.1 Term. The term of this Agreement shall commence on the Effective Date and shall
extend, unless sooner terminated in accordance with the provisions of this Section 4, until
the date that Omeros has fulfilled its Grant Funds repayment obligations, if any, pursuant to this
Agreement.

4.2 Mutual Agreement. The Parties may terminate this Agreement at any time by written
agreement of Omeros and SMRI.

4.3 Termination for Breach.

4.3.1 In the event that Omeros shall be in material breach or default of a material obligation
under this Agreement or the Confidentiality Agreement and shall fail to remedy such breach or
default within sixty (60) days after receipt of written notice thereof given by SMRI, SMRI shall be
entitled
to terminate this Agreement upon written notice to Omeros at any time after such sixty (60) day
period.

4.3.2 In the event that SMRI shall be in material breach or default of a material obligation under
this Agreement or the Confidentiality Agreement and shall fail to remedy such breach or default
within sixty (60) days after receipt of written notice thereof given by Omeros, Omeros shall be
entitled to terminate this Agreement upon written notice to SMRI at any time after such sixty (60)
day period.

4.4 Survival. Termination of this Agreement for any reason shall not release a Party from
any liability which at the time of such termination has already accrued to the other Party,
including Omeros’ remaining obligations, if any, to complete repayment of the Grant Funds pursuant
to this Agreement. The terms of Sections 2.5, 2.6, 3.1, 3.2, 3.4, Section 5 and this Section 4.4
shall survive any termination or expiration of this Agreement, except that the terms of Subsection
3.1.4

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-20-

 

(Interruption License) shall not survive the termination of this Agreement under Section
4.3.2 of this Agreement due to SMRI’s material breach or default. Except as otherwise provided in
this Section 4.4, all rights and obligations of the Parties under this Agreement shall terminate
upon the expiration or termination of this Agreement.

5 Miscellaneous.

5.1 Notice. Any notice or other communication required by this Agreement shall be made in
writing and given by prepaid, first class, certified mail, return receipt requested, and shall be
deemed to have been served on the date received by the addressee at the following address or such
other address as may from time to time be designated by the recipient Party in writing:

If to SMRI:

The Stanley Medical Research Institute

8401 Connecticut Avenue, Suite 200

Chevy Chase, MD 20815

Attn: Executive Director

With copies to:

Bingham McCutchen

3000 K Street, N.W., Suite 300

Washington, DC 20007

Attn: Kenneth I. Schaner, Esq.

If to Omeros:

Omeros Corporation

1420 Fifth Avenue, Suite 2600

Seattle, WA 98101

Attn: Chief Executive Officer

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-21-

 

With copies to:

Omeros Corporation

1420 Fifth Avenue, Suite 2600

Seattle, WA 98101

Attn: General Counsel

5.2 Assignment. This Agreement may not be assigned by either Party without the prior
written consent of the other Party, except that Omeros may assign this Agreement, without such
prior written consent, to a third party that succeeds to all or substantially all of Omeros’
business and assets relating to this Agreement whether by sale, merger, acquisition, change of
control, operation of law or otherwise; provided that any such permitted assignee or transferee
shall be bound by the terms and conditions of this Agreement except as provided in Subsection
3.1.4(b) above.

5.3 License. Omeros may, at its sole discretion, license any or all of the rights in the
Product and/or the Program to any third party. Should Omeros choose to enter into such a licensing
arrangement, the Parties shall remain bound to the terms and conditions of this Agreement.

5.4 Disclosure. In the event that Omeros terminates the Program due to lack of commercial
viability of the Product, Omeros shall, subject to applicable legal and regulatory requirements,
disclose such termination to its shareholders.

5.5 Entire Agreement. This Agreement together with the Confidentiality Agreement set forth
the entire agreement between the Parties with respect to the subject matter herein and replace and
supersede all prior discussions and agreements between them with respect to such subject matter
hereof. This Agreement and the Confidentiality Agreement may not be changed or modified except by
written agreement of the Parties.

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-22-

 

5.6 Relationship of the Parties. Nothing in this Agreement shall be construed to create a
partnership or joint venture between the Parties, nor shall any Party’s employees or agents be
considered the employees or agents of any other. Neither Party shall have any express or implied
right or authority to assume or create any obligation on behalf of, or in the name of, the other
Party or to bind the other Party to any contract, agreement or other obligation with any third
party.

5.7 Governing Law. This Agreement and performance by the parties hereunder shall be
construed in accordance with the laws of the State of Washington, U.S.A., without regard to
provisions on the conflicts of laws.

5.8 Publicity. Omeros shall have the sole right to issue a press release announcing the
transactions contemplated by this Agreement, subject to SMRI’s prior approval of the text of such
press release, which shall not be unreasonably conditioned, withheld or delayed.

5.9 Expenses. All fees and expenses incurred in connection with this Agreement, including
all legal, accounting, financial advisory, consulting and all other fees and expenses of third
parties
(“Third Party Expenses”) incurred by a party in connection with the negotiation and
effectuation of the terms and conditions of this Agreement and the transactions contemplated
hereby, shall be the obligation of the respective party incurring such fees and expenses, [†]. No
broker fees shall be paid in connection with any funding provided to Omeros by SMRI.

5.10 Headings; Signatures. Headings included herein are for convenience only, do not form
a part of this Agreement and shall not be used in any way to construe or interpret this Agreement.
Any reference to “third party” in this Agreement shall mean any person or entity which is not a
Party, including, without limitation, any affiliate of any Party. This Agreement may be executed
in

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-23-

 

counterparts, each of which shall be deemed an original, but both of which together shall
constitute one and the same instrument. This Agreement may be executed by facsimile signature.

5.11 Waiver. No waiver by a Party of any right or remedy hereunder shall be valid unless
the same shall be in writing and signed by the Party giving such waiver. No waiver by a Party with
respect to any default, misrepresentation, or breach of warranty or covenant hereunder shall be
deemed to extend to any prior or subsequent default, misrepresentation, or breach of warranty or
covenant hereunder or affect in any way any rights arising by virtue of any prior or subsequent
such occurrence.

5.12 Validity of Agreement. Any term or provision of this Agreement that is invalid or
unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability
of the remaining terms and provisions hereof or the validity or enforceability of the offending
term or provision in any other situation or in any other jurisdiction. If the final judgment of a
court of competent jurisdiction declares that any term or provision hereof is invalid or
unenforceable, the Parties agree that the court making the determination of invalidity or
unenforceability shall have the power to limit the term or provision, to delete specific words or
phrases, or to replace any invalid or unenforceable term or provision with a term or provision that
is valid and enforceable and that comes closest to expressing the intention of the invalid or
unenforceable term or provision, and this Agreement shall be enforceable as so modified.

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-24-

 

     IN WITNESS WHEREOF, the Parties have caused their duly authorized representatives to execute
this Agreement.

	 	 	 	 	 	 	 	 	 
	THE STANLEY MEDICAL	 	 	 	OMEROS CORPORATION
	RESEARCH INSTITUTE	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	By:

	 	/s/ Michael B. Knable
	 	 	 	By:
	 	/s/ Gregory A. Demopulos
	 

	 	 
	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	Name:

	 	Michael B. Knable, DO
	 	 	 	Name:
	 	Gregory A. Demopulos, M.D.
	 
	 	 	 	 	 	 	 	 
	Title:

	 	Executive Director
	 	 	 	Title:
	 	Chairman & CEO
	 
	 	 	 	 	 	 	 	 
	Date:

	 	12/18/06
	 	 	 	Date:
	 	12/15/06

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

Signature Page to Funding Agreement

 

 

Exhibit Index

	 	 	 
	Exhibit	 	Description
	 
	 	 
	Exhibit A

	 	Certain Defined Terms
	 
	 	 
	Exhibit B

	 	Form of Stock Purchase Agreement
	 
	 	 
	Exhibit C

	 	Form of Investors’ Rights Agreement
	 
	 	 
	Exhibit D

	 	Form of Indemnification Agreement

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

Exhibit Index to Funding Agreement

 

 

EXHIBIT A

DEFINED TERMS RELATING TO NET INCOME AND COMMERCIALIZATION EXPENSES

“Net Income” means income resulting from the Commercial Sale of the Product by Omeros, or
its Affiliate or sublicensee, and shall be equal to Net Sales minus Commercialization
Expenses minus an assumed income tax rate of thirty percent (30%) after taking into account
the deduction accorded Omeros for purposes of calculating taxable income for royalties payable to
SMRI pursuant to this Agreement.

“Net Sales” means the amount invoiced or otherwise billed by Omeros or its Affiliates or
its licensees for sales of the Product to a third party purchaser, less the following to the extent
included in such billing or otherwise actually allowed or incurred with respect to such sales:

     (a) trade and quantity discounts other than early pay cash discounts and which effectively
reduce the selling price and are appropriately deducted from sales under appropriate accounting
principles, consistently applied;

     (b) returns, rebates, chargebacks and other allowances;

     (c) retroactive price reductions that are actually allowed or granted;

     (d) sales commissions paid to third party distributors and/or selling agents, in amounts
customary to the trade;

     (e) a fixed amount equal to [†] of the amount invoiced to cover bad debt, sales or excise
taxes, early payment cash discounts, transportation and insurance, custom duties, and other
governmental charges; and

     (f) the standard inventory cost of devices or delivery systems used for dispensing or
administering the Product (such as syringes and inhalation devices, but excluding packaging).

     With respect to sales of Combination Products, Net Sales in any country shall be calculated on
the basis of the gross invoice price of the Product sold in that country in the absence of the one
or more additional therapeutically active ingredients contained in the Combination Products. In
the event that the Product is sold in a country only as a Combination Product, Net Sales shall be
calculated on the basis of the gross invoice price of the Combination Product multiplied by a
fraction, the numerator of which shall be the average gross invoice price (converted to United
States Dollars) of the Product in any country(ies) in which the Product is sold in the absence of
the one or more additional therapeutically active ingredients contained in the Combination Product
and the denominator of which shall be the average gross invoice price (converted to United States
Dollars) of the Combination Product in those same countries. In the event that the Product is sold
only as the Combination Product in a country and only as the Product alone in any and all other
countries in which the Product is sold, the Net Sales for the Combination Product shall be
calculated based on the average gross invoice price (converted to United States Dollars) of the
Product sold in such other

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

 

country(ies). The deductions set forth in paragraphs (a) through (f) above will be applied in
calculating Net Sales for a Combination Product. In the event that the Product is not sold
anywhere in the world as the Product alone and is sold only as a Combination Product, Omeros shall
reasonably determine the value of the Product relative to the other therapeutically active
ingredients contained in the Combination Product.

“Commercialization Expenses” means Cost of Goods Sold, plus Marketing Expenses
plus Administrative Expenses, plus Third Party Royalties plus Currency
Adjustments.

“Cost of Goods Sold” If the Product is manufactured by one or more third parties, The Cost
of Goods Sold shall equal the actual costs incurred and payable to such third part(ies) by Omeros
for such manufacture (including importation, transportation, handling and logistic charges for
delivery to Omeros to the extent incurred by Omeros and any applicable royalties, other than Third
Party Royalties, payable by Omeros). Cost of Goods Sold shall also include any inventory-related
costs incurred prior to First Commercial Sale to ensure supply of the Product for First Commercial
Sale. If the Product is manufactured by Omeros, then the “Cost of Goods Sold” shall mean Omeros’
actual fully burdened cost for manufacturing the Product, determined in accordance with generally
accepted accounting principles, consistently applied.

“Marketing Expenses” means all direct selling, promotional and medical expenses (including
costs of post-approval clinical studies of the Product) incurred with respect to detailing,
distribution and sampling and marketing of the Product.

“Administrative Expenses” means indirect expenses incurred in supporting the
commercialization of the Product following commercial launch of the Product.

“Third Party Royalties” means any royalty or other fee payments to any third party paid
directly on the manufacture, importation, use, offer for sale or sale of the Product in order to
avoid infringement of any third party right with respect to the manufacture, importation, use,
offer for sale or sale of the Product.

“Currency Adjustments” means quarterly adjustments to actual amounts received by Omeros for
that portion of Net Sales of the Product received in currencies other than United States Dollars.

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-2-

 

EXHIBIT B

OMEROS CORPORATION

TWELFTH ADDENDUM TO SERIES E PREFERRED STOCK

PURCHASE AGREEMENT

     This Twelfth Addendum to Series E Preferred Stock Purchase Agreement (this “Addendum”)
is made as of the                      day of                      by and among Omeros Corporation, a Washington corporation
(the “Company”), and the individuals and entities listed on Exhibit A attached
hereto (the “Additional Purchasers”).

RECITALS

     On March 16, 2004, the Company entered into a Series E Preferred Stock Purchase Agreement (the
“Purchase Agreement”) with certain investors set forth on Exhibit A attached
thereto. The Purchase Agreement provides in Section 1.2(c) thereof that additional investors may,
under conditions set forth therein, become parties to the Purchase Agreement at any time on or
before April 13, 2004 (unless extended by the Company’s Board of Directors). Pursuant to Section
1.2(c) of the Agreement, the Board of Directors has authorized the Additional Purchasers to become
parties to the Purchase Agreement as of the date of this Addendum.

AGREEMENT

     In consideration of the mutual promises, covenants and conditions hereinafter set forth, the
parties hereto mutually agree as follows:

     1. Authorization and Sale of Preferred Stock.

          1.1 Authorization of Preferred Stock. The Company will, prior to the Closing (as
defined in Section 2.1 below), authorize the issuance pursuant to this Addendum of up to                     
shares of its Series E Preferred Stock (the “Additional Shares”). The rights, preferences,
privileges and restrictions of the Series E Preferred Stock are as set forth in the Company’s
Amended and Restated Articles of Incorporation attached as Exhibit B to the Purchase
Agreement, as amended by the Articles of Amendment attached as Attachment 1 to this
Addendum (the “Restated Articles”).

          1.2 Sale of Preferred Stock. Subject to the terms and conditions hereof, at the
Closing the Company will issue and sell to each Additional Purchaser, and each Additional Purchaser
severally agrees to purchase from the Company, that number of Additional Shares specified opposite
such Additional Purchaser’s name on Exhibit A hereto, at a cash purchase price of $5.00 per
share. Each of the Additional Purchasers, by their signatures to the Agreements (as defined in the
Purchase Agreement), shall (i) become parties to the Agreements, (ii) be considered a
“Purchaser” or “Investor,” as the case may be, for all purposes under the
Agreements and (iii) have all the rights and obligations of a Purchaser or Investor, as the case
may be, hereunder and

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

 

thereunder. The Additional Shares acquired by the Additional Purchasers hereunder shall be
considered “Stock” for all purposes under the Purchase Agreement, as amended.

     2. Closing; Delivery.

          2.1 Closing. The closing of the purchase and sale of the Additional Shares hereunder
(the “Closing”) shall be held at the offices of Wilson Sonsini Goodrich & Rosati, P.C., 701
fifth Avenue, Suite 5100, Seattle, Washington, at 10:00 a.m., on                     , or at such other
time and place as the Company and the Additional Purchasers may agree.

          2.2 Delivery. At the Closing, the Company will deliver to each Additional Purchaser a
certificate representing the number of Additional Shares set forth opposite such Additional
Purchaser’s name on Exhibit A, against payment of the purchase price therefor by each
Additional Purchaser by check payable to the Company or by wire transfer to the Company’s bank
account.

     3. Disclosure; Capitalization.

          3.1 Disclosure. Each Additional Purchaser hereby acknowledges receipt of the Purchase
Agreement and the exhibits thereto. The Company affirms to each Additional Purchaser that:

               (i) The representations and warranties of the Company set forth in Section 2 of the Purchase
Agreement were true and accurate when made;

               (ii) Those representations and warranties, which are incorporated herein by this reference and
made a part hereof, remain true and accurate in all material respects as of the date hereof, except
(A) for changes resulting from the transactions contemplated in the Purchase Agreement and (B) as
set forth in the Schedule of Exceptions to Representations and Warranties attached hereto as
Exhibit B.

               (iii) The conditions to closing set forth in Section 4 of the Purchase Agreement and in
Section 5 hereof have been satisfied, provided that the conditions set forth in Section 4.1 of the
Purchase Agreement shall include references to changes in the Company’s representations and
warranties and the Company’s status, respectively, as set forth herein and in the Exhibits attached
hereto, and resulting from the consummation of the transactions contemplated by the Purchase
Agreement.

          3.2 Capitalization. Immediately prior to the Closing, the authorized capital of the
Company shall consist of:

               (i)                      shares of Preferred Stock, of which (i)
                     shares have been designated
Series A Preferred Stock, all of which are issued and outstanding immediately prior to the Closing,
(ii)                      shares have been designated Series B Preferred Stock, all of which are issued and
outstanding immediately prior to the Closing, (iii)                      shares have been designated Series C
Preferred Stock, all of which are issued and outstanding immediately prior to the Closing, (iv)
                     shares have been designated Series D Preferred Stock, of which                     

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-2-

 

shares are issued and outstanding immediately prior to the Closing and (v)                      shares
have been designated Series E Preferred Stock,                      of which are issued and outstanding
immediately prior to the Closing. The rights, privileges and preferences of the Preferred Stock
are as stated in the Restated Articles. All of the outstanding shares of Preferred Stock have been
duly authorized, fully paid and nonassessable and issued in compliance with all applicable federal
and state securities laws.

               (ii)                      shares of Common Stock,                     
 shares of which are issued and outstanding
immediately prior to the Closing. All of the outstanding shares of Common Stock have been duly
authorized, fully paid and are nonassessable and issued in compliance with all applicable federal
and state securities laws.

               (iii) The Company has reserved                      shares of Common Stock for issuance to officers,
directors, employees and consultants of the Company pursuant to its 1998 Stock Option Plan duly
adopted by the Board of Directors and approved by the Company’s shareholders (the “Stock
Plan”). Of such reserved shares of Common Stock,                      shares have been issued pursuant to
restricted stock purchase agreements, options to purchase                      shares have been granted and are
currently outstanding, and                      shares of Common Stock remain available for issuance to
officers, directors, employees and consultants pursuant to the Stock Plan. The Company has
terminated its 1994 Stock Option Plan and all options granted thereunder.

               (iv) Except for outstanding options issued pursuant to the Stock Plan, options to purchase
                     shares of Common Stock issued pursuant to Stock Option Agreements outside the Stock Plan,
warrants to purchase                      shares of Common Stock,                      shares of Common Stock issuable for
assumed options originally issued by nura, inc. under nura, inc.’s 2003 Stock Option Plan,                     
shares of Common Stock and                      shares of Series E Preferred Stock issuable for assumed
warrants originally issued by nura, inc. to Oxford Finance, a warrant to purchase                      shares
of Series D Preferred Stock, certain rights of first offer set forth in the Investors’ Rights
Agreement (as defined in the Purchase Agreement) and potential obligations on the part of the
Company to issue warrants to purchase shares of Series E Preferred Stock at the Closing and any
subsequent Closing(s) (as defined in the Purchase Agreement), there are no outstanding options,
warrants, rights (including conversion or preemptive rights and rights of first refusal or similar
rights) or agreements, orally or in writing, for the purchase or acquisition from the Company of
any shares of its capital stock. The Company is not a party or subject to any agreement or
understanding, and, to the best of the Company’s knowledge, there is no agreement or understanding
between any persons and/or entities, which affects or relates to the voting or giving of written
consents with respect to any security or by a director of the Company.

     4. Representations and Warranties of Additional Purchasers. Each Additional Purchaser
acknowledges that such Additional Purchaser has reviewed the representations and warranties set
forth in Section 3 of the Purchase Agreement and agrees with the Company that such representations
and warranties, which are incorporated herein by this reference and made a part hereof, are true
and correct as of the date hereof as they relate to such Additional Purchaser’s purchase of the
Additional Shares hereunder.

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-3-

 

     5. Conditions to Additional Purchasers’ Obligations at Closing. The obligation of
each Additional Purchaser to purchase the Additional Shares at the Closing is subject to the
fulfillment to such Additional Purchaser’s satisfaction at or prior to the Closing of the following
conditions:

          5.1 Representations and Warranties Correct; Performance of Obligations. The
representations and warranties made by the Company in Section 3 hereof shall be true and correct
when made, and shall be true and correct on the date of the Closing with the same force and effect
as if they had been made on and as of said date, subject to changes contemplated by this Addendum;
and the Company shall have performed all obligations and conditions herein required to be performed
or observed by it at or prior to the Closing.

          5.2 Consents and Waivers. The Company shall have obtained any and all consents and
waivers necessary or appropriate for consummation of the transactions contemplated by this
Addendum.

     6. Conditions to Company’s Obligations at Closing. The obligations of the Company
under Sections 1.1 and 1.2 of this Addendum are subject to the fulfillment at or before the Closing
of each of the following conditions:

          6.1 Representations and Warranties. The representations and warranties of each
Additional Purchaser contained in Section 4 hereof shall be true at the Closing.

          6.2 Consents and Waivers. The Company shall have obtained any and all consents and
waivers necessary or appropriate for the Additional Purchasers to become parties to the Investors’
Rights Agreement and for the consummation of the transactions contemplated by this Addendum.

     7. Miscellaneous.

          7.1 Incorporation by Reference. The provisions set forth in Section 7 of the Purchase
Agreement are incorporated herein by this reference and made a part hereof.

          7.2 Notices. Any notice required or permitted by this Addendum shall be in writing and
shall be deemed sufficient upon delivery, when delivered personally or by overnight courier or sent
by telegram or fax, or forty-eight (48) hours after being deposited in the U.S. mail, as certified
or registered mail, with postage prepaid, addressed to the party to be notified at such party’s
address as set forth on the signature page or Exhibit A hereto, or as subsequently modified
by written notice, and if to the Company, with a copy to Craig Sherman, Wilson Sonsini Goodrich &
Rosati, P.C., 701 Fifth Avenue, Suite 5100, Seattle, Washington 98104.

          7.3 Counterparts. This Addendum may be executed in any number of counterparts, each
of which may be executed by less than all of the Additional Purchasers, each of which shall be
enforceable against the parties actually executing such counterparts, and all of which together
shall constitute one instrument.

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-4-

 

          7.4 Advice of Counsel. Each Purchaser acknowledge that, in executing this Addendum,
such party has had the opportunity to seek the advice of independent legal counsel, and either has
received such advice or has elected not to do so, and in either case, has read and understood all
of the terms and provisions of this Addendum. This Addendum shall not be construed against any
party by reason of the drafting or preparation hereof.

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-5-

 

     The parties hereto have executed this Twelfth Addendum as of the date first set forth above.

	 	 	 	 	 
	 	OMEROS CORPORATION

 	 
	 	By:  	 	 
	 	 	Gregory A. Demopulos, M.D. 	 
	 	 	Chairman of the Board, President and

Chief Executive Officer 	 

	 	 	 	 	 
	 

	 	Address:
	 	1420 Fifth Avenue
	 

	 	 	 	Suite 2600
	 

	 	 	 	Seattle, WA 98101
	 
	 	 	 	 
	 	 	Fax: (206) 264-7856

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

SIGNATURE PAGE TO OMEROS CORPORATION

TWELFTH ADDENDUM TO SERIES E PREFERRED STOCK PURCHASE AGREEMENT

 

 

	 	 	 	 	 
	 	 	ADDITIONAL PURCHASERS:
	 
	 	 	 	 
	 

	 	By:	 	 
	 

	 	 	 	 
	 
	 	 	 	 
	 

	 	Name:	 	 
	 

	 	 	 	 
	 

	 	 	 	(print)
	 
	 	 	 	 
	 

	 	Title:	 	 
	 

	 	 	 	 
	 

	 	 	 	(if appropriate)
	 
	 	 	 	 
	 

	 	Address:	 	 
	 
	 	 	 	 
	 

	 	Fax:	 	 

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

SIGNATURE PAGE TO OMEROS CORPORATION

TWELFTH ADDENDUM TO SERIES E PREFERRED STOCK PURCHASE AGREEMENT

 

 

EXHIBIT C

OMEROS CORPORATION

AMENDED AND RESTATED

INVESTORS’ RIGHTS AGREEMENT

October 15, 2004

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

 

TABLE OF CONTENTS

	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Page	 
	1.	 	Registration Rights	 	 	1	 
	 
	 	 	 	 	 	 	 	 
	 
	 	1.1	 	Definitions	 	 	1	 
	 
	 	1.2	 	Request for Registration	 	 	2	 
	 
	 	1.3	 	Company Registration	 	 	4	 
	 
	 	1.4	 	Form S-3 Registration	 	 	4	 
	 
	 	1.5	 	Obligations of the Company	 	 	5	 
	 
	 	1.6	 	Furnish Information	 	 	6	 
	 
	 	1.7	 	Expenses of Registration	 	 	7	 
	 
	 	1.8	 	Underwriting Requirements	 	 	7	 
	 
	 	1.9	 	Delay of Registration	 	 	8	 
	 
	 	1.10	 	Indemnification	 	 	8	 
	 
	 	1.11	 	Reports Under Securities Exchange Act of 1934	 	 	10	 
	 
	 	1.12	 	Assignment of Registration Rights	 	 	11	 
	 
	 	1.13	 	Limitations on Subsequent Registration Rights	 	 	11	 
	 
	 	1.14	 	Market Stand-Off Agreement	 	 	12	 
	 
	 	1.15	 	Termination of Registration Rights	 	 	12	 
	 
	 	 	 	 	 	 	 	 
	2.	 	Covenants of the Company	 	 	12	 
	 
	 	 	 	 	 	 	 	 
	 
	 	2.1	 	Delivery of Financial Statements	 	 	12	 
	 
	 	2.2	 	Inspection	 	 	13	 
	 
	 	2.3	 	Right of First Offer	 	 	13	 
	 
	 	2.4	 	Termination of Covenants	 	 	15	 
	 
	 	 	 	 	 	 	 	 
	3.	 	Restrictions on Transfer	 	 	15	 
	 
	 	 	 	 	 	 	 	 
	 
	 	3.1	 	Notice of Sales; Right of First Refusal	 	 	15	 
	 
	 	3.2	 	Failure to Exercise	 	 	16	 
	 
	 	3.3	 	No Transfers without Board Approval	 	 	16	 
	 
	 	3.4	 	Permitted Transactions	 	 	16	 
	 
	 	3.5	 	Prohibited Transfers	 	 	17	 
	 
	 	3.6	 	Legended Certificates	 	 	17	 
	 
	 	3.7	 	Termination	 	 	17	 
	 
	 	 	 	 	 	 	 	 
	4.	 	Miscellaneous	 	 	18	 
	 
	 	 	 	 	 	 	 	 
	 
	 	4.1	 	Successors and Assigns	 	 	18	 
	 
	 	4.2	 	Amendments and Waivers	 	 	18	 
	 
	 	4.3	 	Notices	 	 	18	 
	 
	 	4.4	 	Severability	 	 	18	 
	 
	 	4.5	 	Governing Law	 	 	19	 
	 
	 	4.6	 	Counterparts	 	 	19	 
	 
	 	4.7	 	Titles and Subtitles	 	 	19	 
	 
	 	4.8	 	Aggregation of Stock	 	 	19	 
	 
	 	4.9	 	Entire Agreement	 	 	19	 
	 
	 	4.10	 	Telecopy Execution and Delivery	 	 	19	 

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-i-

 

	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Page	 
	 
	 	4.11	 	Arbitration	 	 	19	 
	 
	 	4.12	 	Termination and Supersession	 	 	20	 

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-ii-

 

OMEROS CORPORATION

AMENDED AND RESTATED

INVESTORS’ RIGHTS AGREEMENT

     This Amended and Restated Investors’ Rights Agreement (this “Agreement”) is made as of
the 15th day of October, 2004 by and among Omeros Corporation, a Washington corporation
(the “Company”), the investors listed on Exhibit A hereto (the “Series E
Investors”), H. Raymond Cairncross, Gregory A. Demopulos, M.D., George Kargianis, and Pamela
Pierce Palmer, M.D., Ph.D., each of whom is herein referred to as a “Founder,” the holders
of Series A Preferred Stock of the Company (the “Series A Preferred Stock”) listed on
Exhibit B hereto (the “Series A Investors”), the holders of Series B Preferred
Stock of the Company (the “Series B Preferred Stock”) listed on Exhibit C hereto
(the “Series B Investors”), the holders of Series C Preferred Stock of the Company (the
“Series C Preferred Stock”) listed on Exhibit D hereto (the “Series C
Investors”), the holders of the Series D Preferred Stock of the Company (the “Series D
Preferred Stock”) listed on Exhibit E hereto (the “Series D Investors,” and
together with the Series A Investors, the Series B Investors, the Series C Investors and the Series
E Investors, the “Investors”), and the holders of Common Stock of the Company (the
“Common Stock”) listed on Exhibit F hereto (the “Common Shareholders”).

RECITALS

     The Company, the Founders, the Common Shareholders and the Investors are parties to the
Amended and Restated Investors’ Rights Agreement dated as of March 16, 2004, as amended on
March 19, 2004 (the “Prior Agreement”). The Company issued and sold to the Series E
Investors shares of its Series E Preferred Stock pursuant to the Series E Preferred Stock Purchase
Agreement (the “Purchase Agreement”) dated March 16, 2004 and Addendum Agreements thereto.
A condition to the Series E Investors’ obligations under the Purchase Agreement and the Addendum
Agreements thereto was that the Company, the Founders, the Common Shareholders and the Investors
enter into the Prior Agreement in order to provide the Investors with (i) certain rights to
register shares of Common Stock issuable upon conversion of the Preferred Stock held by the
Investors, (ii) certain rights to receive or inspect information pertaining to the Company, (iii) a
right of first offer with respect to certain issuances by the Company of its securities and (iv) a
right of first refusal upon proposed sales of the Company’s securities held by the Investors and
the Common Shareholders. The Company, the Investors, the Founders and the Common Shareholders each
desire to amend and restate the Prior Agreement in its entirety as set forth herein in order to,
among other things, provide certain of such rights to additional Investors.

AGREEMENT

     The parties hereby agree as follows:

     1. Registration Rights. The Company and the Investors covenant and agree as follows:

          1.1 Definitions. For purposes of this Section 1:

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

 

               (a) The terms “register,” “registered,” and “registration” refer to a
registration effected by preparing and filing a registration statement or similar document in
compliance with the Securities Act of 1933, as amended (the “Securities Act”), and the
declaration or ordering of effectiveness of such registration statement or document;

               (b) The term “Registrable Securities” means (i) the shares of Common Stock issuable or
issued upon conversion of the Series A, Series B, Series C, Series D and Series E Preferred Stock,
(ii) the shares of Common Stock issued to the Founders (the “Founders’ Stock”),
provided, however, that for the purposes of Section 1.2, 1.4 and 1.13 the Founders’
Stock shall not be deemed Registrable Securities and the Founders shall not be deemed Holders, and
(iii) any other shares of Common Stock of the Company issued as (or issuable upon the conversion or
exercise of any warrant, right or other security which is issued as) a dividend or other
distribution with respect to, or in exchange for or in replacement of, the shares listed in (i) and
(ii); provided, however, that the foregoing definition shall exclude in all cases
any Registrable Securities sold by a person in a transaction in which his or her rights under this
Agreement are not assigned. Notwithstanding the foregoing, Common Stock or other securities shall
only be treated as Registrable Securities if and so long as they have not been (A) sold to or
through a broker or dealer or underwriter in a public distribution or a public securities
transaction, or (B) sold in a transaction exempt from the registration and prospectus delivery
requirements of the Securities Act under Section 4(1) thereof so that all transfer restrictions,
and restrictive legends with respect thereto, if any, are removed upon the consummation of such
sale;

               (c) The number of shares of “Registrable Securities then outstanding” shall be
determined by the number of shares of Common Stock outstanding which are, and the number of shares
of Common Stock issuable pursuant to then exercisable or convertible securities which are,
Registrable Securities;

               (d) The term “Holder” means any person owning or having the right to acquire
Registrable Securities or any assignee thereof in accordance with Section 1.12 of this Agreement;

               (e) The term “Form S-3” means such form under the Securities Act as in effect on the
date hereof or any successor form under the Securities Act;

               (f) The term “SEC” means the Securities and Exchange Commission; and

               (g) The term “Qualified IPO” means a firm commitment underwritten public offering by
the Company of shares of its Common Stock pursuant to a registration statement under the Securities
Act, which results in aggregate gross proceeds to the Company of at least $10,000,000.

          1.2 Request for Registration.

               (a) If the Company shall receive at any time after the earlier of (i) three (3) years after
the Closing (as defined in the Purchase Agreement) or (ii) six (6) months

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT FILED SEPARATELY WITH THE COMMISSION

-2-

 

after the effective date
of the first registration statement for a public offering of securities of the Company (other than
a registration statement relating either to the sale of securities to employees of the Company
pursuant to a stock option, stock purchase or similar plan or an SEC Rule 145 transaction), a
written request from the Holders of at least thirty percent (30%) of the Registrable Securities
then outstanding that the Company file a registration statement under the Securities Act covering
the registration of Registrable Securities with an anticipated aggregate gross offering price in
excess of $10,000,000, then the Company shall, within ten (10) days of the receipt thereof, give
written notice of such request to all Holders and shall, subject to the limitations of
subsection 1.2(b), use its best efforts to effect as soon as practicable, and in any event within
60 days of the receipt of such request, the registration under the Securities Act of all
Registrable Securities which the Holders request to be registered within twenty (20) days of the
mailing of such notice by the Company in accordance with Section 4.3.

               (b) If the Holders initiating the registration request hereunder (“Initiating
Holders”) intend to distribute the Registrable Securities covered by their request by means of
an underwriting, they shall so advise the Company as a part of their request made pursuant to this
Section 1.2 and the Company shall include such information in the written notice referred to in
subsection 1.2(a). The underwriter will be selected by a majority in interest of the Initiating
Holders and shall be reasonably acceptable to the Company. In such event, the right of any Holder
to include his Registrable Securities in such registration shall be conditioned upon such Holder’s
participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the
underwriting (unless otherwise mutually agreed by a majority in interest of the Initiating Holders
and such Holder) to the extent provided herein. All Holders proposing to distribute their
securities through such underwriting shall (together with the Company as provided in
subsection 1.5(e)) enter into an underwriting agreement in customary form with the underwriter or
underwriters selected for such underwriting. Notwithstanding any other provision of this
Section 1.2, if the underwriter advises the Initiating Holders in writing that marketing factors
require a limitation of the number of shares to be underwritten, then the Initiating Holders shall
so advise all Holders of Registrable Securities which would otherwise be underwritten pursuant
hereto, and the number of shares of Registrable Securities that may be included in the underwriting
shall be allocated among all Holders thereof, including the Initiating Holders, in proportion (as
nearly as practicable) to the amount of Registrable Securities of the Company owned by each Holder;
provided, however, that the number of shares of Registrable Securities to be
included in such underwriting shall not be reduced unless all other securities are first entirely
excluded from the underwriting.

               (c) Notwithstanding the foregoing, if the Company shall furnish to Holders requesting a
registration statement pursuant to this Section 1.2 a certificate signed by the
President of the Company stating that in the good faith judgment of the Board of Directors of
the Company, it would be seriously detrimental to the Company and its shareholders for such
registration statement to be filed and it is therefore essential to defer the filing of such
registration statement, the Company shall have the right to defer such filing for a period of not
more than 120 days after receipt of the request of the Initiating Holders; provided,
however, that the Company may not utilize this right more than once in any twelve-month
period.

               (d) In addition, the Company shall not be obligated to effect, or to take any action to
effect, any registration pursuant to this Section 1.2:

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT FILED SEPARATELY WITH THE COMMISSION

-3-

 

                    (i) After the Company has effected one (1) registration pursuant to this Section 1.2 and such
registration has been declared or ordered effective;

                    (ii) During the period starting with the date sixty (60) days prior to the Company’s good
faith estimate of the date of filing of, and ending on a date one hundred eighty (180) days after
the effective date of, a registration subject to Section 1.3 hereof; provided that the
Company is actively employing in good faith all reasonable efforts to cause such registration
statement to become effective; or

                    (iii) If the Initiating Holders propose to dispose of shares of Registrable Securities that
may be immediately registered on Form S-3 pursuant to a request made pursuant to Section 1.4 below.

          1.3 Company Registration. If (but without any obligation to do so) the Company
proposes to register (including for this purpose a registration effected by the Company for
shareholders other than the Holders) any of its stock under the Securities Act in connection with
the public offering of such securities solely for cash (other than a registration relating solely
to the sale of securities to participants in a Company stock plan or a transaction covered by
Rule 145 under the Securities Act, a registration in which the only stock being registered is
Common Stock issuable upon conversion of debt securities which are also being registered, or any
registration on any form which does not include substantially the same information as would be
required to be included in a registration statement covering the sale of the Registrable
Securities), the Company shall, at such time, promptly give each Holder written notice of such
registration. Upon the written request of each Holder given within twenty (20) days after mailing
of such notice by the Company in accordance with Section 4.3, the Company shall, subject to the
provisions of Section 1.8, cause to be registered under the Securities Act all of the Registrable
Securities that each such Holder has requested to be registered.

          1.4 Form S-3 Registration. In case the Company shall receive from any Holder or
Holders of not less than twenty percent (20%) of the Registrable Securities then outstanding a
written request or requests that the Company effect a registration on Form S-3 and any related
qualification or compliance with respect to all or a part of the Registrable Securities owned by
such Holder or Holders, the Company will:

               (a) promptly give written notice of the proposed registration, and any related qualification
or compliance, to all other Holders; and

               (b) as soon as practicable, effect such registration and all such qualifications and
compliances as may be so requested and as would permit or facilitate the sale and distribution of
all or such portion of such Holder’s or Holders’ Registrable Securities as are specified in such
request, together with all or such portion of the Registrable Securities of any other Holder or
Holders joining in such request as are specified in a written request given within 15 days after
receipt of such written notice from the Company; provided, however, that the
Company shall not be obligated to effect any such registration, qualification or compliance,
pursuant to this Section 1.4: (i) if Form S-3 is not available for such offering by the Holders;
(ii) if the Holders, together with the holders of any other securities of the Company entitled to
inclusion in such registration, propose to sell Registrable Securities and such other securities
(if

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT FILED SEPARATELY WITH THE COMMISSION

-4-

 

any) at an aggregate price to the public (net of any underwriters’ discounts or commissions) of
less than $2,500,000; (iii) if the Company shall furnish to the Holders a certificate signed by the
President of the Company stating that in the good faith judgment of the Board of Directors of the
Company, it would be seriously detrimental to the Company and its shareholders for such Form S-3
Registration to be effected at such time, in which event the Company shall have the right to defer
the filing of the Form S-3 registration statement for a period of not more than 120 days after
receipt of the request of the Holder or Holders under this Section 1.4; provided,
however, that the Company shall not utilize this right more than once in any twelve month
period; (iv) if the Company has, within the twelve (12) month period preceding the date of such
request, already effected one (1) registration on Form S-3 for the Holders pursuant to this
Section 1.4; (v) in any particular jurisdiction in which the Company would be required to qualify
to do business or to execute a general consent to service of process in effecting such
registration, qualification or compliance; or (vi) during the period ending one hundred eighty
(180) days after the effective date of a registration statement subject to Section 1.3.

               (c) Subject to the foregoing, the Company shall file a registration statement covering the
Registrable Securities and other securities so requested to be registered as soon as practicable
after receipt of the request or requests of the Holders. Registrations effected pursuant to this
Section 1.4 shall not be counted as demands for registration or registrations effected pursuant to
Sections 1.2 or 1.3, respectively.

          1.5 Obligations of the Company. Whenever required under this Section 1 to effect the
registration of any Registrable Securities, the Company shall, as expeditiously as reasonably
possible:

               (a) Prepare and file with the SEC a registration statement with respect to such Registrable
Securities and use its best efforts to cause such registration statement to become effective, and,
upon the request of the Holders of a majority of the Registrable Securities registered thereunder,
keep such registration statement effective for up to one hundred twenty (120) days. The Company
shall not be required to file, cause to become effective or maintain the effectiveness of any
registration statement that contemplates a distribution of securities on a delayed or continuous
basis pursuant to Rule 415 under the Securities Act.

               (b) Prepare and file with the SEC such amendments and supplements to such registration
statement and the prospectus used in connection with such registration statement as may be
necessary to comply with the provisions of the Securities Act with respect to the disposition of
all securities covered by such registration statement for up to one hundred twenty (120) days.

               (c) Furnish to the Holders such numbers of copies of a prospectus, including a preliminary
prospectus, in conformity with the requirements of the Securities Act, and such other documents as
they may reasonably request in order to facilitate the disposition of Registrable Securities owned
by them.

               (d) Use its best efforts to register and qualify the securities covered by such registration
statement under such other securities or Blue Sky laws of such jurisdictions as shall be reasonably
requested by the Holders; provided that the Company shall not be required in

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT FILED SEPARATELY WITH THE COMMISSION

-5-

 

connection therewith or as a condition thereto to qualify to do business or to file a general consent to
service of process in any such states or jurisdictions.

               (e) In the event of any underwritten public offering, enter into and perform its obligations
under an underwriting agreement, in usual and customary form, with the managing underwriter of such
offering. Each Holder participating in such underwriting shall also enter into and perform its
obligations under such an agreement.

               (f) Notify each Holder of Registrable Securities covered by such registration statement at any
time when a prospectus relating thereto is required to be delivered under the Securities Act of the
happening of any event as a result of which the prospectus included in such registration statement,
as then in effect, includes an untrue statement of a material fact or omits to state a material
fact required to be stated therein or necessary to make the statements therein not misleading in
the light of the circumstances, such obligation to continue for so long as the Company is obligated
to maintain the effectiveness of such registration statement.

               (g) Cause all such Registrable Securities registered pursuant hereunder to be listed on each
securities exchange on which similar securities issued by the Company are then listed.

               (h) Provide a transfer agent and registrar for all Registrable Securities registered pursuant
hereunder and a CUSIP number for all such Registrable Securities, in each case not later than the
effective date of such registration.

               (i) Use its best efforts to furnish, at the request of any Holder requesting registration of
Registrable Securities pursuant to this Section 1, on the date that such Registrable Securities are
delivered to the underwriters for sale in connection with a registration pursuant to this
Section 1, if such securities are being sold through underwriters, or, if such securities are not
being sold through underwriters, on the date that the registration statement with respect to such
securities becomes effective, (i) an opinion, dated such date, of the counsel representing the
Company for the purposes of such registration, in form and substance as is customarily given to
underwriters in an underwritten public offering, addressed to the
underwriters, if any, and to the Holders requesting registration of Registrable Securities and
(ii) a letter dated such date, from the independent certified public accountants of the Company, in
form and substance as is customarily given by independent certified public accountants to
underwriters in an underwritten public offering, addressed to the underwriters, if any, and to the
Holders requesting registration of Registrable Securities.

          1.6 Furnish Information. It shall be a condition precedent to the obligations of the
Company to take any action pursuant to this Section 1 with respect to the Registrable Securities of
any selling Holder that such Holder shall furnish to the Company such information regarding itself,
the Registrable Securities held by it, and the intended method of disposition of such securities as
shall be required to effect the registration of such Holder’s Registrable Securities. The Company
shall have no obligation with respect to any registration requested pursuant to Section 1.2 or
Section 1.4 of this Agreement if, as a result of the application of the preceding sentence, the
number of shares or the anticipated aggregate offering price of the

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT FILED SEPARATELY WITH THE COMMISSION

-6-

 

Registrable Securities to be
included in the registration does not equal or exceed the number of shares or the anticipated
aggregate offering price required to originally trigger the Company’s obligation to initiate such
registration as specified in subsection 1.2(a) or subsection 1.4(b)(ii), whichever is applicable.

          1.7 Expenses of Registration.

               (a) Demand Registration. All expenses other than underwriting discounts and
commissions incurred in connection with registrations, filings or qualifications pursuant to
Section 1.2, including (without limitation) all registration, filing and qualification fees,
printers’ and accounting fees, fees and disbursements of counsel for the Company, and the
reasonable fees and disbursements of one counsel for the selling Holders selected by them with the
approval of the Company, which approval shall not be unreasonably withheld, shall be borne by the
Company; provided, however, that the Company shall not be required to pay for any
expenses of any registration proceeding begun pursuant to Section 1.2 if the registration request
is subsequently withdrawn at the request of the Holders of a majority of the Registrable Securities
to be registered (in which case all participating Holders shall bear such expenses), unless the
Holders of a majority of the Registrable Securities agree to forfeit their right to one demand
registration pursuant to Section 1.2; provided, however, that if at the time of
such withdrawal, the Holders have learned of a material adverse change in the condition, business,
or prospects of the Company from that known to the Holders at the time of their request and have
withdrawn the request with reasonable promptness following disclosure by the Company of such
material adverse change, then the Holders shall not be required to pay any of such expenses and
shall retain their rights pursuant to Section 1.2.

               (b) Company Registration. All expenses other than underwriting discounts and
commissions incurred in connection with registrations, filings or qualifications of Registrable
Securities pursuant to Section 1.3 for each Holder (which right may be assigned as provided in
Section 1.12), including (without limitation) all registration, filing, and qualification fees,
printers’ and accounting fees, fees and disbursements of counsel for the Company and the reasonable
fees and disbursements of one counsel for the selling Holder or Holders selected by them with the
approval of the Company, which approval shall not be unreasonably withheld, shall be borne by the
Company.

               (c) Registration on Form S-3. All expenses incurred in connection with a registration
requested pursuant to Section 1.4, including (without limitation) all registration, filing,
qualification, printers’ and accounting fees and the reasonable fees and disbursements of one
counsel for the selling Holder or Holders selected by them with the approval of the Company, which
approval shall not be unreasonably withheld, and counsel for the Company, but not including any
underwriters’ discounts or commissions associated with Registrable Securities, shall be borne by
the Company.

          1.8 Underwriting Requirements. In connection with any offering involving an
underwriting of shares of the Company’s capital stock, the Company shall not be required under
Section 1.3 to include any of the Holders’ securities in such underwriting unless they accept the
terms of the underwriting as agreed upon between the Company and the underwriters selected by it
(or by other persons entitled to select the underwriters), and then only in such

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT FILED SEPARATELY WITH THE COMMISSION

-7-

 

quantity as the
underwriters determine in their sole discretion will not jeopardize the success of the offering by
the Company. If the total amount of securities, including Registrable Securities, requested by
shareholders to be included in such offering exceeds the amount of securities sold other than by
the Company that the underwriters determine in their sole discretion is compatible with the success
of the offering, then the Company shall be required to include in the offering only that number of
such securities, including Registrable Securities, which the underwriters determine in their sole
discretion will not jeopardize the success of the offering (the securities so included to be
apportioned pro rata among the selling shareholders according to the total amount of securities
entitled to be included therein owned by each selling shareholder or in such other proportions as
shall mutually be agreed to by such selling shareholders), but in no event shall (i) any shares
being sold by a shareholder exercising a demand registration right similar to that granted in
Section 1.2 be excluded from such offering, (ii) the amount of securities of the selling Holders of
Preferred Stock included in the offering be reduced below thirty percent (30%) of the total amount
of securities included in such offering, unless such offering is the initial public offering of the
Company’s securities, in which case (except as provided in (i) above) the selling shareholders may
be excluded entirely if the underwriters make the determination described above and no other
shareholder’s securities are included or (iii) any securities held by a Founder be included if any
securities held by any selling Holder are excluded. For purposes of the preceding parenthetical
concerning apportionment, for any selling shareholder which is a holder of Registrable Securities
and which is a partnership or corporation, the partners, retired partners and shareholders of such
holder, or the estates and family members of any such partners and retired partners and any trusts
for the benefit of any of the foregoing persons shall be deemed to be a single “selling
shareholder,” and any pro-rata reduction with respect to such “selling shareholder” shall be
based upon the aggregate amount of shares carrying registration rights owned by all entities and
individuals included in such “selling shareholder,” as defined in this sentence.

          1.9 Delay of Registration. No Holder shall have any right to obtain or seek an
injunction restraining or otherwise delaying any such registration as the result of any controversy
that might arise with respect to the interpretation or implementation of this Section 1.

          1.10 Indemnification. In the event any Registrable Securities are included in a
registration statement under this Section 1:

               (a) To the extent permitted by law, the Company will indemnify and hold harmless each Holder,
the partners, officers, directors and shareholders of each Holder, any underwriter (as defined in
the Securities Act) for such Holder and each person, if any, who controls such Holder or
underwriter within the meaning of the Securities Act or the Securities Exchange Act of 1934, as
amended (the “Exchange Act”), against any losses, claims, damages, or liabilities (joint or
several) to which they may become subject under the Securities Act, the Exchange Act or other
federal or state law, insofar as such losses, claims, damages, or liabilities (or actions in
respect thereof) arise out of or are based upon any of the following statements, omissions or
violations (collectively a “Violation”): (i) any untrue statement or alleged untrue
statement of a material fact contained in such registration statement, including any preliminary
prospectus or final prospectus contained therein or any amendments or supplements thereto, (ii) the
omission or alleged omission to state therein a material fact required to be stated therein,

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT FILED SEPARATELY WITH THE COMMISSION

-8-

 

or necessary to make the statements therein not misleading, or (iii) any violation or alleged
violation by the Company of the Securities Act, the Exchange Act, any state securities law or any
rule or regulation promulgated under the Securities Act, the Exchange Act or any state securities
law; and the Company will pay to each such Holder, underwriter or controlling person, as incurred,
any legal or other expenses reasonably incurred by them in connection with investigating or
defending any such loss, claim, damage, liability, or action; provided, however,
that the indemnity agreement contained in this subsection 1.10(a) shall not apply to amounts paid
in settlement of any such loss, claim, damage, liability, or action if such settlement is effected
without the consent of the Company (which consent shall not be unreasonably withheld), nor shall
the Company be liable to any Holder, underwriter, controlling person or other aforementioned person
for any such loss, claim, damage, liability, or action to the extent that it arises out of or is
based upon a Violation which occurs in reliance upon and in conformity with written information
furnished expressly for use in connection with such registration by any such Holder, underwriter,
controlling person or other aforementioned person.

               (b) To the extent permitted by law, each selling Holder will indemnify and hold harmless the
Company, each of its directors, each of its officers who has signed the registration statement,
each person, if any, who controls the Company within the meaning of the Securities Act, any
underwriter, any other Holder selling securities in such registration statement and any controlling
person of any such underwriter or other Holder, against any losses, claims, damages, or liabilities
(joint or several) to which any of the foregoing persons may become subject, under the Securities
Act, the Exchange Act or other federal or state law, insofar as such losses, claims, damages, or
liabilities (or actions in respect thereto) arise out of or are based upon any Violation, in each
case to the extent (and only to the extent) that such Violation occurs in reliance upon and in
conformity with written information furnished by such Holder expressly for use in connection with
such registration; and each such Holder will pay, as incurred, any legal or other expenses
reasonably incurred by any person intended to be indemnified pursuant to this
subsection 1.10(b), in connection with investigating or defending any such loss, claim,
damage, liability, or action; provided, however, that the indemnity agreement
contained in this subsection 1.10(b) shall not apply to amounts paid in settlement of any such
loss, claim, damage, liability or action if such settlement is effected without the consent of the
Holder, which consent shall not be unreasonably withheld; provided, that in no event shall
any indemnity under this subsection 1.10(b) exceed the net proceeds from the offering received by
such Holder, except in the case of willful fraud by such Holder.

               (c) Promptly after receipt by an indemnified party under this Section 1.10 of notice of the
commencement of any action (including any governmental action), such indemnified party will, if a
claim in respect thereof is to be made against any indemnifying party under this Section 1.10,
deliver to the indemnifying party a written notice of the commencement thereof and the indemnifying
party shall have the right to participate in, and, to the extent the indemnifying party so desires,
jointly with any other indemnifying party similarly noticed, to assume the defense thereof with
counsel mutually satisfactory to the parties; provided, however, that an
indemnified party (together with all other indemnified parties which may be represented without
conflict by one counsel) shall have the right to retain one separate counsel, with the reasonable
fees and expenses to be paid by the indemnifying party, if representation of such indemnified party
by the counsel retained by the indemnifying party would be inappropriate due to actual or potential
differing interests between such indemnified

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT FILED SEPARATELY WITH THE COMMISSION

-9-

 

party and any other party represented by such counsel
in such proceeding. The failure to deliver written notice to the indemnifying party within a
reasonable time of the commencement of any such action, if prejudicial to its ability to defend
such action, shall relieve such indemnifying party of any liability to the indemnified party under
this Section 1.10, but the omission so to deliver written notice to the indemnifying party will not
relieve it of any liability that it may have to any indemnified party otherwise than under this
Section 1.10.

               (d) If the indemnification provided for in this Section 1.10 is held by a court of competent
jurisdiction to be unavailable to an indemnified party with respect to any loss, liability, claim,
damage or expense referred to therein, then the indemnifying party, in lieu of indemnifying such
indemnified party hereunder, shall contribute to the amount paid or payable by such indemnified
party as a result of such loss, liability, claim, damage, or expense in such proportion as is
appropriate to reflect the relative fault of the indemnifying party on the one hand and of the
indemnified party on the other in connection with the statements or omissions that resulted in such
loss, liability, claim, damage or expense as well as any other relevant equitable considerations;
provided that in no event shall any contribution by a Holder under this subsection 1.10(d)
exceed the net proceeds from the offering received by such Holder, except in the case of willful
fraud by such Holder. The relative fault of the indemnifying party and of the indemnified party
shall be determined by reference to, among other things, whether the untrue or alleged untrue
statement of a material fact or the omission to state a material fact relates to information
supplied by the indemnifying party or by the indemnified party and the parties’ relative intent,
knowledge, access to information, and opportunity to correct or prevent such statement or omission.

               (e) Notwithstanding the foregoing, to the extent that the provisions on indemnification and
contribution contained in the underwriting agreement entered into in
connection with the underwritten public offering are in conflict with the foregoing
provisions, the provisions in the underwriting agreement shall control.

               (f) The obligations of the Company and Holders under this Section 1.10 shall survive the
completion of any offering of Registrable Securities in a registration statement under this
Section 1, and otherwise.

          1.11 Reports Under Securities Exchange Act of 1934. With a view to making available
to the Holders the benefits of Rule 144 promulgated under the Securities Act and any other rule or
regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the
public without registration or pursuant to a registration on Form S-3, the Company agrees to:

               (a) make and keep public information available, as those terms are understood and defined in
SEC Rule 144, at all times after ninety (90) days after the effective date of the first
registration statement filed by the Company for the offering of its securities to the general
public so long as the Company remains subject to the periodic reporting requirements under
Sections 13 or 15(d) of the Exchange Act;

               (b) take such action, including the voluntary registration of its Common Stock under
Section 12 of the Exchange Act, as is necessary to enable the Holders to

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT FILED SEPARATELY WITH THE COMMISSION

-10-

 

utilize Form S-3 for the
sale of their Registrable Securities, such action to be taken as soon as practicable after the end
of the fiscal year in which the first registration statement filed by the Company for the offering
of its securities to the general public is declared effective;

               (c) file with the SEC in a timely manner all reports and other documents required of the
Company under the Securities Act and the Exchange Act; and

               (d) furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith
upon request (i) a written statement by the Company that it has complied with the reporting
requirements of SEC Rule 144 (at any time after ninety (90) days after the effective date of the
first registration statement filed by the Company), the Securities Act and the Exchange Act (at any
time after it has become subject to such reporting requirements), or that it qualifies as a
registrant whose securities may be resold pursuant to Form S-3 (at any time after it so qualifies),
(ii) a copy of the most recent annual or quarterly report of the Company and such other reports and
documents so filed by the Company, and (iii) such other information as may be reasonably requested
in availing any Holder of any rule or regulation of the SEC which permits the selling of any such
securities without registration or pursuant to such form.

          1.12 Assignment of Registration Rights. The rights to cause the Company to register
Registrable Securities pursuant to this Section 1 may be assigned (but only with all related
obligations) by a Holder to a transferee or assignee of such securities that (i) is a subsidiary,
parent, partner, limited partner, retired partner or shareholder of a Holder; (ii) is a Holder’s
family member or trust for the benefit of an individual Holder; or (iii) after such assignment or
transfer, holds at least 200,000 shares of such securities, provided the Company is, within
a reasonable time after such transfer, furnished with written notice of the name and address of
such transferee or
assignee and the securities with respect to which such registration rights are being assigned;
and provided, further, that such assignment shall be effective only if immediately
following such transfer the further disposition of such securities by the transferee or assignee is
restricted under the Securities Act. For the purposes of determining the number of shares of
Registrable Securities held by a transferee or assignee, the holdings of transferees and assignees
of a partnership who are partners or retired partners of such partnership (including spouses and
ancestors, lineal descendants and siblings of such partners or spouses who acquire Registrable
Securities by gift, will or intestate succession) shall be aggregated together and with the
partnership; provided that all assignees and transferees who would not qualify individually
for assignment of registration rights shall have a single attorney-in-fact for the purpose of
exercising any rights, receiving notices or taking any action under Section 1.

          1.13 Limitations on Subsequent Registration Rights. From and after the date of this
Agreement, the Company shall not, without the prior written consent of the Holders of a majority of
the outstanding Registrable Securities (except as otherwise provided in Section 4.2 hereof), enter
into any agreement with any holder or prospective holder of any securities of the Company which
would allow such holder or prospective holder (a) to include such securities in any registration
filed under Section 1.2 hereof, unless under the terms of such agreement, such holder or
prospective holder may include such securities in any such registration only to the extent that the
inclusion of his securities will not reduce the amount of the Registrable Securities of the Holders
which is included or (b) to make a demand for registration of such securities.

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT FILED SEPARATELY WITH THE COMMISSION

-11-

 

          1.14 “Market Stand-Off” Agreement. Each Holder, Founder, Investor and Common
Shareholder (collectively, the “Shareholders”) hereby agrees that, during the period of
duration (up to, but not exceeding, 180 days) specified by the Company and an underwriter of Common
Stock or other securities of the Company, following the effective date of a registration statement
of the Company filed under the Securities Act, it shall not, to the extent requested by the Company
and such underwriter, directly or indirectly sell, offer to sell, contract to sell (including,
without limitation, any short sale), grant any option to purchase or otherwise transfer or dispose
of (other than to donees who agree to be similarly bound) any securities of the Company held by it
at any time during such period except Common Stock included in such registration; provided,
however, that:

               (a) such agreement shall be applicable only to the first such registration statement of the
Company which covers Common Stock (or other securities) to be sold on its behalf to the public in
an underwritten offering; and

               (b) all officers and directors of the Company, all one-percent or greater securityholders, and
all other persons with registration rights (whether or not pursuant to this Agreement) enter into
similar agreements.

          In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions
with respect to the Registrable Securities of each Shareholder (and the shares or securities of
every other person subject to the foregoing restriction) until the end of such period, and each
Shareholder agrees that, if so requested, such Shareholder will execute an
agreement in the form provided by the underwriter containing terms which are essentially
consistent with the provisions of this Section 1.14.

          Notwithstanding the foregoing, the obligations described in this Section 1.14 shall not apply
to a registration relating solely to employee benefit plans on Form S-1 or Form S-8 or similar
forms which may be promulgated in the future, or a registration relating solely to an SEC Rule 145
transaction on Form S-4 or similar forms which may be promulgated in the future.

          1.15 Termination of Registration Rights. No Holder shall be entitled to exercise any
right provided for in this Section 1 after the earlier of (i) five (5) years following the
consummation of a Qualified IPO, or (ii) such time as Rule 144 or another similar exemption under
the Securities Act is available for the sale of all of such Holder’s shares during a consecutive
three (3)-month period without registration.

     2. Covenants of the Company.

          2.1 Delivery of Financial Statements. The Company shall deliver to each Holder of at
least 200,000 shares of Registrable Securities (other than a Holder reasonably deemed by the
Company to be a competitor of the Company):

               (a) as soon as practicable, but in any event within ninety (90) days after the end of each
fiscal year of the Company, an income statement for such fiscal year, a balance sheet of the
Company and statement of shareholder’s equity as of the end of such year, and a statement of cash
flows for such year, such year-end financial reports to be in reasonable

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT FILED SEPARATELY WITH THE COMMISSION

-12-

 

detail, prepared in
accordance with generally accepted accounting principles (“GAAP”), and audited and
certified by an independent public accounting firm of nationally recognized standing selected by
the Company;

               (b) as soon as practicable, but in any event within forty-five (45) days after the end of each
of the first three (3) quarters of each fiscal year of the Company, an unaudited profit or loss
statement, a statement of cash flows for such fiscal quarter and an unaudited balance sheet as of
the end of such fiscal quarter; and

               (d) as soon as practicable, but in any event thirty (30) days prior to the end of each fiscal
year, a budget and business plan for the next fiscal year, prepared on a quarterly basis, and, as
soon as prepared, any other budgets or revised budgets prepared by the Company.

          2.2 Inspection. The Company shall permit each Holder of at least 200,000 shares of
Registrable Securities (except for a Holder reasonably deemed by the Company to be a competitor of
the Company), at such Holder’s expense, to visit and inspect the Company’s properties, to examine
its books of account and records and to discuss the Company’s affairs, finances and accounts with
its officers, all at such reasonable times as may be requested by the Investor; provided,
however, that the Company shall not be obligated pursuant to this Section 2.2 to provide
access to any information which it reasonably considers to be a trade secret or similar
confidential information.

          2.3 Right of First Offer. Subject to the terms and conditions specified in this
Section 2.3, the Company hereby grants to each Major Investor (as hereinafter defined) a right of
first offer with respect to future sales by the Company of its Shares (as hereinafter defined).
For purposes of this Section 2.3, a “Major Investor” shall mean any person who holds at
least 200,000 shares of Series B, Series C, Series D and/or Series E Preferred Stock (or Common
Stock issued upon conversion of such shares of Series B, Series C, Series D and/or Series E
Preferred Stock), as adjusted for stock dividends, stock splits, reclassifications and the like.
For purposes of this Section 2.3, Major Investor includes any general partners and affiliates of a
Major Investor. A Major Investor that chooses to exercise the right of first offer may designate
as purchasers under such right itself or its partners or affiliates in such proportions as it deems
appropriate.

          Each time the Company proposes to offer any shares of, or securities convertible into or
exercisable for any shares of, any class of its capital stock (for purposes of this Section 2.3,
the “Shares”), the Company shall first make an offering of such Shares to each Major
Investor in accordance with the following provisions:

               (a) The Company shall deliver a notice by certified mail (“Notice”) to the Major
Investors stating (i) its bona fide intention to offer such Shares, (ii) the number of such Shares
to be offered, and (iii) the price and terms, if any, upon which it proposes to offer such Shares.

               (b) Within 15 calendar days after delivery of the Notice, the Major Investor may elect to
purchase or obtain, at the price and on the terms specified in the Notice, up

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT FILED SEPARATELY WITH THE COMMISSION

-13-

 

to that portion of
such Shares which equals the proportion that the number of shares of Common Stock issued and held,
or issuable upon conversion and exercise of all convertible or exercisable securities then held, by
such Major Investor bears to the total number of shares of Common Stock then outstanding (assuming
full conversion and exercise of all convertible securities, warrants or options). The Company
shall promptly, in writing, inform each Major Investor that purchases all the shares available to
it (each, a “Fully-Exercising Investor”) of any other Major Investor’s failure to do
likewise. During the ten (10)-day period commencing after receipt of such information, each
Fully-Exercising Investor shall be entitled to obtain that portion of the Shares for which Major
Investors were entitled to subscribe but which were not subscribed for by the Major Investors that
is equal to the proportion that the number of shares of Common Stock issued and held, or issuable
upon conversion and exercise of all convertible or exercisable securities then held, by such
Fully-Exercising Investor bears to the total number of shares of Common Stock then outstanding
(assuming full conversion and exercise of all convertible or exercisable securities, warrants or
options).

               (c) The Company may, during the 45-day period following the expiration of the period provided
in subsection 2.3(b) hereof, offer the remaining unsubscribed portion of the Shares to any person
or persons at a price not less than, and upon terms no more favorable to the offeree than those
specified in the Notice. If the Company does not enter into an agreement for the sale of the
Shares within such period, or if such agreement is not consummated within 60 days of the execution
thereof, the right provided hereunder shall be deemed to be revived and such Shares shall not be
offered unless first reoffered to the Major Investors in accordance herewith.

               (d) The right of first offer in this paragraph 2.3 shall not be applicable (i) to the issuance
or sale of shares of Common Stock (or options therefor) to employees, officers, consultants and
directors, vendors or others with whom the Company conducts business pursuant to a stock option
plan or restricted stock plan approved by the Board of Directors for the primary purpose of
soliciting or retaining their services, (ii) to or after consummation of a Qualified IPO, (iii) to
the issuance of securities pursuant to the conversion or exercise of convertible or exercisable
securities, (iv) to the issuance of securities in connection with a bona fide business acquisition
of or by the Company, whether by merger, consolidation, sale of assets, sale or exchange of stock
or otherwise, or similar transaction, the terms of which are approved by the Board of Directors of
the Company, (v) to the issuance of securities to financial institutions or lessors in connection
with commercial credit arrangements, equipment financings, or similar transactions, or that are for
other than primarily equity financing purposes, (vi) to the issuance or sale of the Series E
Preferred Stock or warrants to purchase the Series E Preferred Stock, (vii) to the issuance of
securities that, with unanimous approval of the Board of Directors of the Company, are not offered
to any existing shareholder of the Company, or (viii) to the issuance of securities in connection
with a transaction approved by the Board of Directors of the Company to an entity as a component of
a business relationship with such entity also involving material manufacturing, marketing,
distribution, product development and/or technology licensing arrangements. In addition to the
foregoing, the right of first offer in this paragraph 2.3 shall not be applicable with respect to
any Investor and any subsequent securities issuance, if (i) at the time of such subsequent
securities issuance, the Investor is not an “accredited investor,” as that term is then defined in
Rule 501(a) under the Securities Act, and (ii) such subsequent securities issuance is otherwise
being offered only to accredited investors.

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT FILED SEPARATELY WITH THE COMMISSION

-14-

 

          2.4 Termination of Covenants.

               (a) The covenants set forth in Sections 2.1 through Section 2.3 shall terminate as to each
Holder and be of no further force or effect (i) immediately prior to the closing of a Qualified
IPO, or (ii) when the Company shall sell, convey, or otherwise dispose of or encumber all or
substantially all of its property or business or merge into or consolidate with any other
corporation (other than a wholly-owned subsidiary corporation) or effect any other transaction or
series of related transactions in which more than fifty percent (50%) of the voting power of the
Company is disposed of, provided that this subsection (ii) shall not apply to a merger
effected exclusively for the purpose of changing the domicile of the Corporation.

               (b) The covenants set forth in Sections 2.1 and 2.2 shall terminate as to each Holder and be
of no further force or effect when the Company first becomes subject to the periodic reporting
requirements of Sections 13 or 15(d) of the Exchange Act, if this occurs earlier than the events
described in Section 2.4(a).

     3. Restrictions on Transfer.

          3.1 Notice of Sales; Right of First Refusal.

               (a) Should any Shareholder propose to accept one or more bona fide offers (collectively, a
“Purchase Offer”) from any person(s) or entity(ies) to purchase any shares
of the Company’s capital stock or portions thereof held by such Shareholder (for purposes of
this Section 3, the “Shares”) (other than as set forth in Section 3.4 hereof), such
Shareholder shall promptly deliver a notice (the “Notice”) to the Company stating the terms
and conditions of such Purchase Offer including, without limitation, the number of shares of the
Company’s capital stock to be sold or transferred, the nature of such sale or transfer, the
consideration to be paid, and the name and address of each prospective purchaser or transferee.
The Company shall then have the right, exercisable by notice to the selling Shareholder within
thirty (30) days after receipt of the Notice (the “Initial Company Refusal Period”), to
exercise a first right to purchase all or a portion of such Shares (the “Initial Company Right
of First Refusal”) on the same terms and conditions as described in the Notice.

               (b) If the Company does not exercise the Initial Company Right of First Refusal in full and
the sale of the Shares by such Shareholder has been approved by a two-thirds majority of the Board
of Directors of the Company pursuant to Section 3.3 hereof, then promptly after the expiration of
the Initial Company Refusal Period, the Company shall send a written notice, which notice shall
include the Notice from the selling Shareholder (together the “Second Notice”), to each
Investor stating that the Company has chosen not to exercise, in full or in part, the Initial
Company Right of First Refusal. The Company shall then have the right, exercisable by notice to
the selling Shareholder within thirty (30) days after the date of the Second Notice (the
“Subsequent Company Refusal Period”), to exercise a first right to purchase all or a
portion of such Shares (the “Subsequent Company Right of First Refusal”) on the same terms
and conditions as described in the Notice. Each Investor shall have the secondary right, subject
to the Subsequent Company Right of First Refusal, exercisable by notice to the selling Shareholder
and to the Company within twenty (20) days after the Second Notice (the “Refusal Period”),
to exercise a right to purchase such Shares not purchased by the Company (the “Right

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT FILED SEPARATELY WITH THE COMMISSION

-15-

 

of First
Refusal”) on the same terms and conditions as described in the Notice and on a pro rata basis,
based upon the number of shares of Common Stock issued and held, or issuable upon conversion and
exercise of all convertible or exercisable securities then held, by such Investor relative to the
aggregate number of shares of Common Stock issued and held, or issuable upon conversion and
exercise of all convertible or exercisable securities then held, by all Investors; provided
that if fewer than all Investors elect to participate, the Shares that would otherwise be allocated
to non-participating Investors shall be allocated to each participating Investor in a manner such
that each participating Investor is entitled to purchase at least such Investor’s pro rata portion
of such unallocated or such different number of Shares as the participating Investors shall
mutually agree. Upon expiration of the Subsequent Company Refusal Period, the Company will provide
notice to all Investors as to whether or not the Subsequent Company Right of First Refusal has been
exercised by the Company, and to the extent that it has not, as to whether or not the Right of
First Refusal has been exercised by one or more of the Investors.

          3.2 Failure to Exercise. The failure by the Company or an Investor to exercise the
rights under Section 3.1 or Section 3.3 to purchase any portion of Shares in a sale of Shares made
by a Shareholder shall not affect the Company’s or such Investor’s rights to purchase any portion
of Shares in subsequent sales of Shares by any Shareholder.

          3.3 No Transfers without Board Approval. Except for transfers to the Company pursuant
to Section 3.1 and except as permitted pursuant to Section 3.4, no Shareholder may transfer any
shares of capital stock of the Company (including without limitation to Investors pursuant to
Section 3.1(b)) without first obtaining the written consent to such transfer from a two-thirds
majority of the Company’s Board of Directors, such two-thirds majority in its good faith judgment,
having determined that such transfer would not be detrimental to the interests of the Company and
its shareholders. In addition, as a condition precedent to any such transfer, the transferee must
agree in writing to be bound by the terms of this Section 3.3 as if such transferee were a
Shareholder under this Section 3.3, and to be bound by all other provisions of this Agreement
applicable to the transferor.

          3.4 Permitted Transactions. The provisions of Section 3.1 and Section 3.3 of this
Agreement shall not pertain or apply to:

               (a) any pledge of the Company’s capital stock made by a Shareholder pursuant to a bona fide
loan transaction which creates a mere security interest;

               (b) any bona fide gift;

               (c) any transfer to a Shareholder’s ancestors, descendants or spouse or to a trust for their
benefit;

               (d) any sale or transfer of shares of Common Stock among the Shareholders;

               (e) any sale or transfer by a Shareholder of up to 5% of the total number of shares of Common
Stock held by such Shareholder on the date of this Agreement in any twelve-month period;
provided that the pledgee, transferee or donee (collectively, the

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-16-

 

“Permitted
Transferees”) shall furnish the other Shareholders with a written agreement to be bound by and
comply with all provisions of this Agreement applicable to the Shareholders; or

               (f) any transfer by a Shareholder that is a partnership to a partner of such partnership or a
retired partner of such partnership who retires after the date hereof, or to the estate of any such
partner or retired partner or the transfer by gift, will or intestate succession of any partner to
his or her spouse or to the siblings, lineal descendants or ancestors of such partner or his or her
spouse.

          3.5 Prohibited Transfers. Any attempt by a Shareholder to transfer shares of the
Company in violation of Section 3 hereof shall be void, and the Company agrees it will not effect
such a transfer nor will it treat any alleged transferee as the holder of such shares without the
written consent of the holders of a two-thirds majority of the Shareholders, voting as a single
class on a fully diluted, as-converted basis, and the written consent of a two-thirds majority of
the Board of Directors of the Company.

          3.6 Legended Certificates. Each certificate representing shares of the Series A,
Series B, Series C, Series D and Series E Preferred Stock and Common Stock now owned by the
Shareholders or issued to any Permitted Transferee pursuant to Section 3.4 shall bear the following
legend:

“THE SALE, PLEDGE, HYPOTHECATION OR TRANSFER OF THE SECURITIES REPRESENTED BY THIS
CERTIFICATE IS SUBJECT TO THE TERMS AND CONDITIONS OF A CERTAIN RESTRICTIONS
AGREEMENT BY AND BETWEEN THE SHAREHOLDER, THE CORPORATION AND CERTAIN HOLDERS OF
COMMON AND PREFERRED STOCK OF THE CORPORATION. COPIES OF SUCH
AGREEMENT MAY BE OBTAINED UPON WRITTEN REQUEST TO THE SECRETARY OF THE CORPORATION.”

     The foregoing legend shall be removed upon termination of this Agreement in accordance with
the provisions of Section 3.7.

          3.7 Termination. The obligations and restrictions contained in this Section 3 shall
terminate upon the earliest to occur of any one of the following events (and shall not apply to any
transfer by a Shareholder in connection with any such event):

               (a) the liquidation, dissolution or indefinite cessation of the business operations of the
Company;

               (b) the execution by the Company of a general assignment for the benefit of creditors or the
appointment of a receiver or trustee to take possession of the property and assets of the Company;

               (c) the consummation of a Qualified IPO; or

               (d) the sale, conveyance, disposal, or encumbrance of all or substantially all of the
Company’s property or business or the Company’s merger into or

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-17-

 

consolidation with any other
corporation (other than a wholly-owned subsidiary corporation) or if the Company effects any other
transaction or series of related transactions in which more than fifty percent (50%) of the voting
power of the Company is disposed of; provided that this Section 3.7(d) shall not apply to a
merger effected exclusively for the purpose of changing the domicile of the Company.

     4. Miscellaneous.

          4.1 Successors and Assigns. Except as otherwise provided in this Agreement, the terms
and conditions of this Agreement shall inure to the benefit of and be binding upon the respective
permitted successors and assigns of the parties (including transferees of any of the Preferred
Stock or any Common Stock issued upon conversion thereof). Nothing in this Agreement, express or
implied, is intended to confer upon any party other than the parties hereto or their respective
successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this
Agreement, except as expressly provided in this Agreement.

          4.2 Amendments and Waivers. Any term of this Agreement may be amended or waived only
with the written consent of the Company and the holders of a majority of the Registrable Securities
then outstanding, not including the Founders’ Stock; provided that if such amendment has
the effect of affecting the Founders’ Stock (i) in a manner different than securities issued to the
Investors and (ii) in a manner adverse to the interests of the holders of the Founders’ Stock, then
such amendment shall require the consent of the holder or holders of a majority of the Founders’
Stock. Notwithstanding the foregoing, subsequent Purchasers (as defined under the Purchase
Agreement) of the Company’s Series E Preferred Stock under the Purchase Agreement or any
Addendum Agreement thereto will be added as a party to this Agreement as an Investor without
having to obtain the consents set forth above and shall be bound by and entitled to the terms,
benefits and conditions herein by the execution and delivery of a signature page to this Agreement.
Any amendment or waiver effected in accordance with this paragraph shall be binding upon each
holder of any Registrable Securities then outstanding, each future holder of all such Registrable
Securities, and the Company.

          4.3 Notices. Unless otherwise provided, any notice required or permitted by this
Agreement shall be in writing and shall be deemed sufficient upon delivery, when delivered
personally or by overnight courier or sent by telegram or fax with electronic confirmation
received, or forty-eight (48) hours after being deposited in the U.S. mail, as certified or
registered mail, with postage prepaid, and addressed to the party to be notified at such party’s
address or fax number as set forth on the signature page or Exhibits hereto or as subsequently
modified by written notice.

          4.4 Severability. If one or more provisions of this Agreement are held to be
unenforceable under applicable law, the parties agree to renegotiate such provision in good faith.
In the event that the parties cannot reach a mutually agreeable and enforceable replacement for
such provision, then (a) such provision shall be excluded from this Agreement, (b) the balance of
this Agreement shall be interpreted as if such provision were so excluded and (c) the balance of
this Agreement shall be enforceable in accordance with its terms.

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-18-

 

          4.5 Governing Law. This Agreement and all acts and transactions pursuant hereto shall
be governed, construed and interpreted in accordance with the laws of the State of Washington,
without giving effect to principles of conflicts of laws.

          4.6 Counterparts. This Agreement may be executed in two or more counterparts, each of
which shall be deemed an original, but all of which together shall constitute one and the same
instrument.

          4.7 Titles and Subtitles. The titles and subtitles used in this Agreement are used
for convenience only and are not to be considered in construing or interpreting this Agreement.

          4.8 Aggregation of Stock. All shares of the Preferred Stock held or acquired by
affiliated entities or persons shall be aggregated together for the purpose of determining the
availability of any rights under this Agreement.

          4.9 Entire Agreement. This Agreement (including the Exhibits hereto, if any)
constitutes the entire understanding among the parties with regard to the subjects hereof and
thereof.

          4.10 Telecopy Execution and Delivery. A facsimile, telecopy or other reproduction of
this Agreement may be executed by one or more parties hereto, and an executed copy of this
Agreement may be
delivered by one or more parties hereto by facsimile or similar electronic transmission device
pursuant to which the signature of or on behalf of such party can be seen, and such execution and
delivery shall be considered valid, binding and effective for all purposes. At the request of any
party hereto, all parties hereto agree to execute an original of this Agreement as well as any
facsimile, telecopy or other reproduction hereof.

          4.11 Arbitration. The parties agree to attempt in good faith to negotiate a
settlement of any and all controversies, claims, or disputes arising out of, relating to, or
resulting from this Agreement. If, after such good faith negotiation, the parties are not able to
reach a settlement, any and all of such controversies, claims, or disputes arising out of, relating
to, or resulting from this Agreement shall be subject to binding arbitration. Such arbitration
shall take place in Seattle, Washington and will be administered by the American Arbitration
Association (“AAA”) in accordance with its Rules for the Resolution of Commercial Disputes.
The parties agree that the arbitrator shall have the power to decide any motions brought by any
party to the arbitration, including motions for summary judgment and/or adjudication and motions to
dismiss and demurrers, prior to any arbitration hearing. The parties also agree that the
arbitrator shall have the power to award any remedies, including attorneys’ fees and costs,
available under applicable law, provided that the prevailing party in any arbitration shall be
entitled to its reasonable attorneys fees and costs. The decision of the arbitrator shall be in
writing. Arbitration shall be the sole, exclusive and final remedy for any dispute under this
Agreement and the decision of the arbitrator may be entered by a party in any court or forum, state
or federal, being of competent jurisdiction. Accordingly, no party will be permitted to pursue
court action regarding this Agreement except as expressly permitted in the preceding sentence.
Notwithstanding the foregoing, each party retains the right to seek injunctive relief to prevent a

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-19-

 

breach, threatened breach or continuing breach of this Agreement that would cause irreparable
injury to such party.

          4.12 Termination and Supersession. This Agreement replaces and supersedes the Prior
Agreement, and the Prior Agreement is hereby terminated.

[Signature Page Follows]

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-20-

 

     The parties have executed this Amended and Restated Investors’ Rights Agreement as of the date
first above written.

	 	 	 	 	 	 	 
	 	 	COMPANY:	 	 
	 
	 	 	 	 	 	 
	 	 	OMEROS CORPORATION	 	 
	 
	 	 	 	 	 	 
	 

	 	By:	 	 	 	 
	 

	 	 	 	 

Gregory A. Demopulos, M.D.
	 	 
	 

	 	 	 	Chairman of the Board, President and	 	 
	 

	 	 	 	Chief Executive Officer	 	 

	 	 	 	 	 
	 

	 	Address:
	 	1420 Fifth Ave., Suite 2600
	 

	 	 	 	Seattle, WA 98101
	 
	 	 	 	 
	 

	 	 	 	Fax: (206) 264-7856

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

SIGNATURE PAGE TO OMEROS CORPORATION’S

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

 

 

	 	 	 	 	 	 	 
	 	 	SERIES E INVESTOR:	 	 
	 
	 	 	 	 	 	 
	 	 	 	 	 
	 	 	(Investor)	 	 
	 
	 	 	 	 	 	 
	 

	 	By:	 	 	 	 
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 

	 	Name:	 	 	 	 
	 

	 	 	 	 	 	 
	 

	 	(print)	 	 	 	 
	 
	 	 	 	 	 	 
	 

	 	Title:	 	 	 	 
	 

	 	 	 	 	 	 
	 	 	(if applicable)	 	 
	 
	 	 	 	 	 	 
	 

	 	Address
	 	:	 	 
	 
	 	 	 	 	 	 
	 

	 	Fax:	 	 	 	 

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

SIGNATURE PAGE TO OMEROS CORPORATION’S

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

 

 

	 	 	 	 	 	 	 
	 	 	FOUNDERS:	 	 
	 
	 	 	 	 	 	 
	 	 	 	 	 
	 	 	H. Raymond Cairncross	 	 
	 
	 	 	 	 	 	 
	 	 	Address:	 	 
	 
	 	 	 	 	 	 
	 

	 	Fax:	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	 	 	 
	 	 	Gregory A. Demopulos, M.D.	 	 
	 
	 	 	 	 	 	 
	 

	 	Address:
	 	 	 	 
	 
	 	 	 	 	 	 
	 

	 	Fax:	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	 	 	 
	 	 	George Kargianis	 	 
	 
	 	 	 	 	 	 
	 	 	Address:	 	 
	 
	 	 	 	 	 	 
	 

	 	Fax:	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	 	 	 
	 	 	Pamela Pierce Palmer, M.D., Ph.D.	 	 
	 
	 	 	 	 	 	 
	 

	 	Address:
	 	 	 	 
	 
	 	 	 	 	 	 
	 

	 	Fax:	 	 	 	 

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

SIGNATURE PAGE TO OMEROS CORPORATION’S

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

 

 

	 	 	 	 	 	 	 
	 	 	SERIES A INVESTOR:	 	 
	 
	 	 	 	 	 	 
	 	 	 	 	 
	 	 	(Investor)	 	 
	 
	 	 	 	 	 	 
	 

	 	By:	 	 	 	 
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 

	 	Name:	 	 	 	 
	 

	 	 	 	 	 	 
	 

	 	 	 	(print)	 	 
	 
	 	 	 	 	 	 
	 

	 	Title:	 	 	 	 
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	Address:	 	 
	 
	 	 	 	 	 	 
	 

	 	Fax:	 	 	 	 

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

SIGNATURE PAGE TO OMEROS CORPORATION’S

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

 

 

	 	 	 	 	 	 	 
	 	 	SERIES B INVESTOR:	 	 
	 
	 	 	 	 	 	 
	 	 	 	 	 
	 	 	(Investor)	 	 
	 
	 	 	 	 	 	 
	 

	 	By:	 	 	 	 
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 

	 	Name:	 	 	 	 
	 

	 	 	 	 	 	 
	 

	 	 	 	(print)	 	 
	 
	 	 	 	 	 	 
	 

	 	Title:	 	 	 	 
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	Address:	 	 
	 
	 	 	 	 	 	 
	 

	 	Fax:	 	 	 	 

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

SIGNATURE PAGE TO OMEROS CORPORATION’S

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

 

 

	 	 	 	 	 	 	 
	 	 	SERIES C INVESTOR:	 	 
	 
	 	 	 	 	 	 
	 	 	 	 	 
	 	 	(Investor)	 	 
	 
	 	 	 	 	 	 
	 

	 	By:	 	 	 	 
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 

	 	Name:	 	 	 	 
	 

	 	 	 	 	 	 
	 

	 	 	 	(print)	 	 
	 
	 	 	 	 	 	 
	 

	 	Title:	 	 	 	 
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	Address:	 	 
	 
	 	 	 	 	 	 
	 

	 	Fax:	 	 	 	 

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

SIGNATURE PAGE TO OMEROS CORPORATION’S

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

 

 

	 	 	 	 	 	 	 
	 	 	SERIES D INVESTOR:	 	 
	 
	 	 	 	 	 	 
	 	 	 	 	 
	 	 	(Investor)	 	 
	 
	 	 	 	 	 	 
	 

	 	By:	 	 	 	 
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 

	 	Name:	 	 	 	 
	 

	 	 	 	 	 	 
	 

	 	 	 	(print)	 	 
	 

	 	Title:	 	 	 	 
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	Address:	 	 
	 
	 	 	 	 	 	 
	 

	 	Fax:	 	 	 	 

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

SIGNATURE PAGE TO OMEROS CORPORATION’S

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

 

 

	 	 	 	 	 	 	 
	 	 	COMMON SHAREHOLDER:	 	 
	 
	 	 	 	 	 	 
	 	 	 	 	 
	 	 	(Common Shareholder)	 	 
	 
	 	 	 	 	 	 
	 

	 	By:	 	 	 	 
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 

	 	Name:	 	 	 	 
	 

	 	 	 	 	 	 
	 

	 	 	 	(print)	 	 
	 
	 	 	 	 	 	 
	 

	 	Title:	 	 	 	 
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	Address:	 	 
	 
	 	 	 	 	 	 
	 

	 	Fax:	 	 	 	 

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

SIGNATURE PAGE TO OMEROS CORPORATION’S

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

 

 

EXHIBIT D

INDEMNIFICATION AGREEMENT

          This
Indemnification Agreement (this “Agreement”) is made as of                      ___, ___ by
and between Omeros Corporation, a Washington corporation (the “Company”) and
                     (“Indemnitee”).

RECITALS

     A. Indemnitee is an officer or director of the Company and in such capacity is performing
valuable services for the Company.

     B. The Company and Indemnitee recognize the difficulty in obtaining directors’ and officers’
liability insurance, the significant cost of such insurance and the general reduction in the
coverage of such insurance.

     C. The Company and Indemnitee further recognize the substantial increase in litigation
subjecting officers and directors to expensive litigation risks at the same time that such
liability insurance has been severely limited.

     D. As of the date hereof, the Company has provisions for indemnification of its directors and
officers in Article VIII of its Articles of Incorporation (the “Articles of Incorporation”)
and Article VII of its Bylaws (the “Bylaws”) which provide for indemnification of the
Company’s directors and officers to the fullest extent permitted by the Washington Business
Corporation Act (the “Statute”).

     E. The Bylaws and the Statute specifically provide that they are not exclusive, and thereby
contemplate that contracts may be entered into between the Company and the members of its Board of
Directors and its officers with respect to indemnification of such directors and officers.

     F. The Bylaws provide that the Company may maintain, at its expense, insurance to protect
itself and any of its directors and officers against liability asserted against such persons
incurred in such capacity whether or not the Company has the power to indemnify such persons
against the same liability under Section 23B.08.510 or .520 of the Statute or a successor statute.

     G. In order to induce Indemnitee to continue to serve as an officer and/or director, as the
case may be, of the Company, the Company has agreed to enter into this Agreement with Indemnitee.

AGREEMENT

     In consideration of the recitals above, the mutual covenants and agreements herein contained,
and Indemnitee’s continued service as an officer and/or director, as the case may be, of the
Company after the date hereof, the parties to this Agreement agree as follows:

     1. Indemnity of Indemnitee

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

 

          (a) Scope. The Company agrees to hold harmless and indemnify Indemnitee to the full
extent permitted by law, notwithstanding that such indemnification is not specifically authorized
by this Agreement, the Company’s Articles of Incorporation, the Bylaws, the Statute or otherwise.
In the event of any change, after the date of this Agreement, in any applicable law, statute or
rule regarding the right of a Washington corporation to indemnify a member of its board of
directors or an officer, such changes, to the extent that they would expand Indemnitee’s rights
hereunder, shall be within the purview of Indemnitee’s rights and the Company’s obligations
hereunder, and, to the extent that they would narrow Indemnitee’s rights hereunder, shall be
excluded from this Agreement; provided, however, that any change that is required by applicable
laws, statutes or rules to be applied to this Agreement shall be so applied regardless of whether
the effect of such change is to narrow Indemnitee’s rights hereunder.

          (b) Nonexclusivity. The indemnification provided by this Agreement shall not be
deemed exclusive of any rights to which Indemnitee may be entitled under the Company’s Articles of
Incorporation, the Bylaws, any agreement, any vote of shareholders or disinterested directors, the
Statute, or otherwise, whether as to action in Indemnitee’s official capacity or otherwise.

          (c) Additional Indemnity. If Indemnitee was or is made a party, or is threatened to
be made a party, to or is otherwise involved (including, without limitation, as a witness) in any
Proceeding (as defined below), the Company shall hold harmless and indemnify Indemnitee from and
against any and all losses, claims, damages, liabilities, expenses (including attorneys’ fees),
judgments, fines, ERISA excise taxes or penalties, amounts paid in settlement (if such settlement
is approved in advance by the Company, which approval shall not be unreasonably withheld) actually
and reasonably incurred by Indemnitee in connection with such Proceeding if Indemnitee acted in
good faith and in a manner Indemnitee reasonably believed to be in or not opposed to the best
interests of the Company, and, with respect to any criminal action or proceeding, had no reasonable
cause to believe Indemnitee’s conduct was unlawful (collectively, “Damages”).

          (d) Definition of Proceeding. For purposes of this Agreement, “Proceeding”
shall mean any actual, pending or threatened action, suit, claim or proceeding, whether civil,
criminal, administrative or investigative and whether formal or informal, in which Indemnitee is,
was or becomes involved by reason of the fact that Indemnitee is or was a director, officer,
employee or agent of the Company or that, being or having been such a director, officer, employee
or agent, Indemnitee is or was serving at the request of the Company as a director, officer,
employee, trustee or agent of another corporation or of a partnership, joint venture, trust or
other enterprise (collectively a “Related Company”), including service with respect to an
employee benefit plan, whether the basis of such proceeding is alleged action (or inaction) by
Indemnitee in an official capacity as a director, officer, employee, trustee or agent or in any
other capacity while serving as a director, officer, employee, trustee or agent; provided, however,
that, except with respect to an action to enforce the provisions of this Agreement, Proceeding
shall not include any action, suit, claim or proceeding instituted by or at the direction of
Indemnitee unless such action, suit, claim or proceeding is or was authorized by the Company’s
Board of Directors.

          (e) Determination of Entitlement. In the event that a determination of Indemnitee’s
entitlement to indemnification is required pursuant to Section 23B.08.550 of the

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-2-

 

Statute or any successor thereto or pursuant to other applicable law, the appropriate
decision-maker shall make such determination; provided, however, that Indemnitee shall initially be
presumed in all cases to be entitled to indemnification, that Indemnitee may establish a conclusive
presumption of any fact necessary to such a determination by delivering to the Company a
declaration made under penalty of perjury that such fact is true and that, unless the Company shall
deliver to Indemnitee written notice of a determination that Indemnitee is not entitled to
indemnification within twenty (20) days of the Company’s receipt of Indemnitee’s initial written
request for indemnification, such determination shall conclusively be deemed to have been made in
favor of the Company’s provision of indemnification and Company hereby agrees not to assert
otherwise.

          (f) Survival. The indemnification provided under this Agreement shall apply to any
and all Proceedings, notwithstanding that Indemnitee has ceased to be a director, officer,
employee, trustee or agent of the Company or a Related Company.

     2. Expense Advances

          (a) Generally. The right to indemnification of Damages conferred by Section 1 shall
include the right to have the Company pay Indemnitee’s expenses in any Proceeding as such expenses
are incurred and in advance of such Proceeding’s final disposition (such right is referred to
hereinafter as an “Expense Advance”). Any Expense Advance to be made under this Agreement
shall be paid by the Company to Indemnitee within twenty (20) days following delivery of a written
request therefor by Indemnitee to the Company.

          (b) Conditions to Expense Advance. The Company’s obligation to provide an Expense
Advance is subject to the following conditions:

               (i) Undertaking. If the Proceeding arose in connection with Indemnitee’s service as a
director or officer of the Company (and not in any other capacity in which Indemnitee rendered
service, including service to any Related Company), then Indemnitee or his or her representative
shall have executed and delivered to the Company an undertaking, which need not be secured and
shall be accepted without reference to Indemnitee’s financial ability to make repayment, by or on
behalf of Indemnitee to repay all Expense Advances if and to the extent that it shall ultimately be
determined by a final, unappealable decision rendered by a court having jurisdiction over the
parties and the question that Indemnitee is not entitled to be indemnified for such Expense Advance
under this Agreement or otherwise.

               (ii) Cooperation. Indemnitee shall give the Company such information and cooperation
as it may reasonably request and as shall be within Indemnitee’s power.

               (iii) Affirmation. Indemnitee shall furnish, upon request by the Company and if
required under applicable law, a written affirmation of Indemnitee’s good faith belief that any
applicable standards of conduct have been met by Indemnitee.

     3. Procedures for Enforcement

          (a) Enforcement. In the event that a claim for indemnity, an Expense Advance or
otherwise is made hereunder and is not paid in full within sixty (60) days (twenty

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-3-

 

(20) days for an Expense Advance) after written notice of such claim is delivered to the
Company, Indemnitee may, but need not, at any time thereafter bring suit against the Company to
recover the unpaid amount of the claim (an “Enforcement Action”).

          (b) Presumptions in Enforcement Action. In any Enforcement Action the following
presumptions (and limitation on presumptions) shall apply:

               (i) The Company shall conclusively be presumed to have entered into this Agreement and assumed
the obligations imposed on it hereunder in order to induce Indemnitee to continue as an officer
and/or director, as the case may be, of the Company;

               (ii) Neither (A) the failure of the Company (including the Company’s Board of Directors,
independent or special legal counsel or the Company’s shareholders) to have made a determination
prior to the commencement of the Enforcement Action that indemnification of Indemnitee is proper in
the circumstances nor (B) an actual determination by the Company, its Board of Directors,
independent or special legal counsel or shareholders that Indemnitee is not entitled to
indemnification shall be a defense to the Enforcement Action or create a presumption that
Indemnitee is not entitled to indemnification hereunder; and

               (iii) If Indemnitee is or was serving as a director, officer, employee, trustee or agent of a
corporation of which a majority of the shares entitled to vote in the election of its directors is
held by the Company or in an executive or management capacity in a partnership, joint venture,
trust or other enterprise of which the Company or a wholly owned subsidiary of the Company is a
general partner or has a majority ownership, then such corporation, partnership, joint venture,
trust or enterprise shall conclusively be deemed a Related Company and Indemnitee shall
conclusively be deemed to be serving such Related Company at the request of the Company.

          (c) Attorneys’ Fees and Expenses for Enforcement Action. In the event Indemnitee is
required to bring an Enforcement Action, the Company shall indemnify and hold harmless Indemnitee
against all of Indemnitee’s fees and expenses in bringing and pursuing the Enforcement Action
(including attorneys’ fees at any stage, including on appeal); provided, however, that the Company
shall not be required to provide such indemnity for such attorneys’ fees or expenses if a court of
competent jurisdiction determines that each of the material assertions made by Indemnitee in such
Enforcement Action was not made in good faith or was frivolous.

     4. Limitations on Indemnity; Mutual Acknowledgment

          (a) Limitation on Indemnity. No indemnity pursuant to this Agreement shall be
provided by the Company:

               (i) On account of any suit in which a final, unappealable judgment is rendered against
Indemnitee for an accounting of profits made from the purchase or sale by Indemnitee of securities
of the Company in violation of the provisions of Section 16(b) of the Securities Exchange Act of
1934 and amendments thereto;

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-4-

 

               (ii) For Damages that have been paid directly to Indemnitee by an insurance carrier under a
policy of officers’ and directors’ liability insurance maintained by the Company;

               (iii) On account of Indemnitee’s conduct which is finally adjudged to have been intentional
misconduct, a knowing violation of law or the RCW 23B.08.310 or any successor provision of the
Statute, or a transaction from which Indemnitee derived benefit in money, property or services to
which Indemnitee is not legally entitled; or

               (iv) If a final decision by a court having jurisdiction in the matter shall determine that
such indemnification is not lawful.

          (b) Mutual Acknowledgment. The Company and Indemnitee acknowledge that, in certain
instances, federal law or public policy may override applicable state law and prohibit the Company
from indemnifying Indemnitee under this Agreement or otherwise. For example, the Company and
Indemnitee acknowledge that the Securities and Exchange Commission (the “SEC”) has taken
the position that indemnification is not permissible for liabilities arising under certain federal
securities laws, and federal legislation prohibits indemnification for certain ERISA violations.
Furthermore, Indemnitee understands and acknowledges that the Company has undertaken or may be
required in the future to undertake with the SEC to submit the question of indemnification to a
court in certain circumstances for a determination of the Company’s right under public policy to
indemnify Indemnitee.

     5. Notification and Defense of Claim

          (a) Notification. Promptly after receipt by Indemnitee of notice of the commencement
of any Proceeding, Indemnitee will, if a claim in respect thereof is to be made against the Company
under this Agreement, notify the Company of the commencement thereof; but the omission so to notify
the Company will not relieve the Company from any liability which it may have to Indemnitee under
this Agreement unless and only to the extent that such omission can be shown to have prejudiced the
Company’s ability to defend the Proceeding.

          (b) Defense of Claim. With respect to any such Proceeding as to which Indemnitee
notifies the Company of the commencement thereof:

               (i) The Company may participate therein at its own expense;

               (ii) The Company, jointly with any other indemnifying party similarly notified, may assume the
defense thereof, with counsel satisfactory to Indemnitee. After notice from the Company to
Indemnitee of its election so to assume the defense thereof, the Company shall not be liable to
Indemnitee under this Agreement for any legal or other expenses (other than reasonable costs of
investigation) subsequently incurred by Indemnitee in connection with the defense thereof unless
(A) the employment of counsel by Indemnitee has been authorized by the Company, (B) Indemnitee
shall have reasonably concluded that there may be a conflict of interest between the Company and
Indemnitee in the conduct of the defense of such action, or (C) the Company shall not in fact have
employed counsel to assume the defense of such action, in each of which cases the fees and expenses
of counsel shall be at the expense of the Company.

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-5-

 

The Company shall not be entitled to assume the defense of any action, suit or proceeding
brought by or on behalf of the Company or as to which Indemnitee shall have made the conclusion
provided for in (B) above;

               (iii) The Company shall not be liable to indemnify Indemnitee under this Agreement for any
amounts paid in settlement of any Proceeding effected without its written consent;

               (iv) The Company shall not settle any action or claim in any manner which would impose any
penalty or limitation on Indemnitee without Indemnitee’s written consent; and

               (v) Neither the Company nor Indemnitee will unreasonably withhold its, his or her consent to
any proposed settlement.

          (c) Notice to Insurers. If, at the time of the receipt of a notice of a claim
pursuant to Section 5(a) hereof, the Company has director and officer liability insurance in
effect, the Company shall give prompt notice of the commencement of such proceeding to the insurers
in accordance with the procedures set forth in the respective policies. The Company shall
thereafter take all necessary or desirable action to cause such insurers to pay, on behalf of the
Indemnitee, all amounts payable as a result of such proceeding in accordance with the terms of such
policies.

     6. Severability. Nothing in this Agreement is intended to require or shall be construed
as requiring the Company to do or fail to do any act in violation of applicable law. The Company’s
inability, pursuant to court order, to perform its obligations under this Agreement shall not
constitute a breach of this Agreement. The provisions of this Agreement shall be severable, as
provided in this Section 6. If this Agreement or any portion hereof shall be invalidated on any
ground by any court of competent jurisdiction, then the Company shall nevertheless indemnify
Indemnitee to the full extent permitted by any applicable portion of this Agreement that shall not
have been invalidated, and the balance of this Agreement not so invalidated shall be enforceable in
accordance with its terms.

     7. No Employment Rights. Nothing contained in this Agreement is intended to create in
Indemnitee any right to continued employment.

     8. Officer and Director Liability Insurance. The Company shall, from time to time, make
the good faith determination whether or not it is practicable for the Company to obtain and
maintain a policy or policies of insurance with reputable insurance companies providing the
officers and directors of the Company with coverage for losses from wrongful acts, or to ensure the
Company’s performance of its indemnification obligations under this Agreement. Among other
considerations, the Company will weigh the costs of obtaining such insurance coverage against the
protection afforded by such
coverage. In all policies of director and officer liability insurance, Indemnitee shall be
named as an insured in such a manner as to provide Indemnitee the same rights and benefits as are
accorded to the most favorably insured of the Company’s directors, if Indemnitee is a director; or
of the Company’s officers, if Indemnitee is not a director of the Company but is an officer; or of
the Company’s key employees, if

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-6-

 

Indemnitee is not an officer or director but is a key employee.
Notwithstanding the foregoing, the Company shall have no obligation to obtain or maintain such
insurance if the Company determines in good faith that such insurance is not reasonably available,
if the premium costs for such insurance are disproportionate to the amount of coverage provided, if
the coverage provided by such insurance is limited by exclusions so as to provide an insufficient
benefit, or if Indemnitee is covered by similar insurance maintained by a parent or subsidiary of
the Company.

     9. Partial Indemnification. If Indemnitee is entitled under any provision of this
Agreement to indemnification by the Company for some or a portion of the expenses, judgments, fines
or penalties actually or reasonably incurred in the investigation, defense, appeal or settlement of
any civil or criminal action, suit or proceeding, but not, however, for the total amount thereof,
the Company shall nevertheless indemnify Indemnitee for the portion of such expenses, judgments,
fines or penalties to which Indemnitee is entitled.

     10. Miscellaneous

          (a) Governing Law. This Agreement and all acts and transactions pursuant hereto and
the rights and obligations of the parties hereto shall be governed, construed and interpreted in
accordance with the laws of the State of Washington, without giving effect to principles of
conflict of law.

          (b) Entire Agreement, Enforcement of Rights. This Agreement sets forth the entire
agreement and understanding of the parties relating to the subject matter herein and merges all
prior discussions between them. No modification of or amendment to this Agreement, nor any waiver
of any rights under this Agreement, shall be effective unless in writing signed by the parties to
this Agreement. The failure by either party to enforce any rights under this Agreement shall not
be construed as a waiver of any rights of such party.

          (c) Construction. This Agreement is the result of negotiations between and has been
reviewed by each of the parties hereto and their respective counsel, if any; accordingly, this
Agreement shall be deemed to be the product of all of the parties hereto, and no ambiguity shall be
construed in favor of or against any one of the parties hereto.

          (d) Notices. Any notice, demand or request required or permitted to be given under
this Agreement shall be in writing and shall be deemed sufficient when delivered personally or sent
by telegram or forty-eight (48) hours after being deposited in the U.S. mail, as certified or
registered mail, with postage prepaid, and addressed to the party to be notified at such party’s
address as set forth below or as subsequently modified by written notice.

          (e) Counterparts. This Agreement may be executed in two or more counterparts, each of
which shall be deemed an original and all of which together shall constitute one instrument.

          (f) Successors and Assigns. This Agreement shall be binding upon Indemnitee and upon
the Company, its successors and assigns, and shall inure to the benefit of Indemnitee, Indemnitee’s
heirs, personal representatives and assigns and to the benefit of the Company, its successors and
assigns.

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-7-

 

          (g) Subrogation. In the event of payment under this Agreement, the Company shall be
subrogated to the extent of such payment to all of the rights of recovery of Indemnitee, who shall
execute all documents required and shall do all acts that may be necessary to secure such rights
and to enable the Company to effectively bring suit to enforce such rights.

[Signature page follows]

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-8-

 

     IN WITNESS WHEREOF, the parties hereto have executed this Agreement on and as of the day and
year first above written.

	 	 	 	 	 	 	 
	 	 	OMEROS CORPORATION	 	 
	 
	 	 	 	 	 	 
	 

	 	By:	 	 	 	 
	 

	 	 	 	 

[Name]
	 	 
	 

	 	 	 	[Title]	 	 
	 
	 	 	 	 	 	 
	 	 	Address:	 	 
	AGREED TO AND ACCEPTED:
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	[Name]
	 	 	 	 	 	 
	 
	 

(Signature)

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	Address:
	 	 	 	 	 	 

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

SIGNATURE PAGE TO OMEROS CORPORATION’S

INDEMNIFICATION AGREEMENT

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00158-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00158-of-00352.parquet"}]]